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ABSTRACT 
Peng Gong: Utilizing Molecular Dynamics to Study Conformation and Conformational Dynamics of 
Cisplatin and Oxaliplatin Adducts with DNA 
(Under the direction of Stephen G. Chaney) 
 
Cis-diamminedichloroplatinum(II) (cisplatin, CP) is a widely used anti-cancer agent. Its platinum 
analog (trans-R,R)1,2-diaminocyclohexaneoxalatoplatinum(II) (oxaliplatin, OX) is often effective in 
cisplatin resistant tumors and generally causes less mutation than CP. Although their carrier ligands are 
structurally distinct, CP and OX form the same types of adducts at the same sites on the DNA. Certain DNA 
regulatory proteins could distinguish CP-DNA adducts from OX-DNA adducts but the underlying 
mechanism is not clear currently. In this thesis, we utilized molecular dynamics computer simulation to 
study these two adducts and we found that DNA was more distorted on the 5’ side of the adduct than the 3’ 
side, CP adduct was oriented more towards the 5’ side of the adduct and OX adduct more towards the 3’ 
side and some significant differences were observed in the frequency distributions of DNA duplex helical 
parameters, which may provide an explanation to their distinct biological properties. 
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CHAPTER 1 BACKGROUND 
 
1.1 Cisplatin is a potent platinum agent in chemotherapy against cancers 
Cisplatin (CP) or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based drug used in 
chemotherapy to treat cancers, such as testicular, ovarian, bladder, gullet (oesophagus), stomach, head, neck 
and non-small cell lung cancer.  
 
1.1.1 Chemical structure of cisplatin 
Cisplatin is a surprisingly simple inorganic compound and its chemical structure in 2D and 3D is 
shown in Figure 1.1. Cisplatin has a square-planar structure, with central platinum (Pt) coordinated by two 
chloride (Cl) ion ligands cis to each other and other two ammonia (NH3) ligands also in cis.  
 
 
Figure 1.1 The chemical structures of cisplatin and oxaliplatin in 2D and 3D. The upper panel is the 
chemical structure of cisplatin in 2D and 3D, the central platinum atom in big gray ball, chloride in green, 
nitrogen in blue and hydrogen in small gray ball. The lower panel is the chemical structure of oxaliplatin in 
2D and 3D, the central platinum atom in big gray ball, oxygen in red, nitrogen in blue, carbon in black and 
hydrogen in small gray ball.  
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1.1.2 History of discovery of cisplatin 
Cisplatin is a chemical compound discovered in 1844 and was only found to have anticancer properties 
in 1970s by accident. As a chemical compound, cisplatin was first synthesized by M. Peyrone in 1844 and 
had been called Peyrone's chloride. Its chemical structure was first elucidated by Alfred Werner in 1893. In 
the early 1960s cisplatin was rediscovered by Barnett Rosenberg et. al. at Michigan State University in a 
series of experiments designed to elucidate the effect of electric fields on the bacterial growth of E. coli. 
What they observed was that the bacteria grew into an elongated form, 300 times the normal length, and 
unexpectedly, ceased to divide. After careful examination a year later the cause of inhibition of bacteria 
division was shown not to be due to the electric fields but rather a platinum compound formed in a reaction 
between the platinum electrodes and components of the solution. Further tests revealed that this platinum 
compound could prevent cell divisions through inhibition of cell mitosis, but not other growth processes in 
the bacteria, resulting in bacteria elongation. This serendipitous discovery soon initiated a series of 
investigations and studies into the effects of platinum compounds on cell division. In 1970, further studies 
by Barnett Rosenberg revealed that some platinum compounds had significant anticancer activity and 
demonstrated that diamminedichloroplatinum(II), specifically the cis isomer cisplatin, was extremely 
effective against sarcoma 180 and L1210 leukemia in mice. Cisplatin was the first member of its class to be 
approved for clinical use by the American Food and Drug Administration (FDA) in 1978. Cisplatin has 
been one of the most effective, widely used and most profitable antineoplastics in the world. 
 
1.1.3 Mechanism of cisplatin against tumors 
The clinical efficacy of cisplatin in chemotherapy against tumors is thought to be primarily due to the 
formation of cisplatin-DNA adducts which interfere with cellular repair and replication, and therefore 
trigger a chain of cell regulatory events, ultimately leading to cell death.  
 
The details of formation of cisplatin-DNA adducts are as follows. The uncharged cisplatin is able to 
cross the cell membrane and enter the cell. The relatively low concentration of chloride in cytosol favors the 
substitution of chloride ions with water molecules. This results in positively charged, active, aquated 
species, which can be easily attacked by a variety of macromolecules possessing nucleophilic groups, 
including DNA. While platinum adducts with protein and RNA are more abundant, the Pt-DNA adducts are 
thought to be responsible for killing the cell. Cisplatin can form coordinated covalent bonds with 
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nucleophilic sites on nucleic acid bases in DNA. Its preferential binding sites are the N7 atom of guanine 
base especially in regions of two or more consecutive guanines, and to a lesser extent, the N7 atom of 
adenine base when it is located 5’ to a guanine(4) (Figure 1.2). Generally speaking, cisplatin is a 
bifunctional agent and can bind to two sites in DNA. The resulting biadducts are composed of 
approximately 60-65% 1,2-intrastrand GG, 25-30% 1,2-intrastrand AG, 5-10% 1,3-intrastrand GNG and 
1-3% interstrand GG(1) (Figure 1.2).   
 
1.1.4 Side effects and limitations of cisplatin 
Cisplatin is cytotoxic and has severe toxic side effects in clinical practices, such as nephrotoxicity, 
neurotoxicity, ototoxicity, extremely severe nausea and vomiting, and other toxic manifestations common 
among anticancer agents. In addition, although the mutagenicity of cisplatin has not been officially 
determined or acknowledged, the International Agency for Research on Cancer (IARC) has classified 
cisplatin as a probable human carcinogen(2). Furthermore, acquired resistance can develop against cisplatin 
in some types of tumors during the treatment process, which reduces the clinical efficacy of cisplatin. All of 
the above side effects and limitations of cisplatin have promoted research and development of second 
generation platinum agents, which are designed to have greater clinical effectiveness, reduced cytotoxicity 
and modified, more “friendly” pharmacological properties. Oxaliplatin is such a successful successor.  
 
1.2 Oxaliplatin is the second generation platinum analog of cisplatin 
Studies have shown that even minor variation of the carrier ligands of platinum complex could 
possibly have a profound effect on its anticancer activity and cytotoxicity. For example, almost all 
trans-compounds tested are ineffective, while the cis-counterparts are quite the opposite. After screening 
hundreds of platinum complexes, there are only a few successful ones, of which one is oxaliplatin (OX) or 
(trans-R,R)1,2-diaminocyclohexaneoxalatoplatinum(II). Oxaliplatin is a much bigger organic compound 
and its chemical structure in 2D and 3D is shown in Figure 1.1. Compared to cisplatin, the two amine NH3 
ligands in cisplatin are substituted by the (trans-R,R)1,2-diaminocyclohexane (DACH) ligand in oxaliplatin 
in order to improve antitumour activity; the two chloride ion ligands in cisplatin are replaced by the oxalato 
bidentate ligand derived from oxalic acid in oxaliplatin in order to improve water solubility. Although 
structurally distinct from each other, studies have shown that cisplatin and oxaliplatin form the same types 
of adducts at the same sites in DNA(5). Cisplatin forms cisplatin-DNA adduct with cis-diammine carrier 
 4
ligand and oxaliplatin forms oxaliplatin-DNA adduct with much bulkier DACH carrier ligand (Figure 1.2). 
However, oxaliplatin is generally more effective in certain cisplatin-resistant cell lines(3) and the FDA 
approved its clinical usage for the treatment of colorectal cancer and other cisplatin-resistant tumors in 2004. 
Oxaliplatin has become the third most widely used platinum agent in the world for treatment of cancer.  
 
Figure 1.2 Formation of cisplatin-DNA and oxaliplatin-DNA adducts. The upper panel shows the three 
major kinds of Pt-DNA biadducts. The red bar represents the nucleotide which is coordinated by the 
platinum adduct. The lower panel illustrates how the two chloride ion ligands of cisplatin and the oxalato 
bidentate ligand of oxaliplatin are substituted by the N7 atom from two guanines or one adenine. 
 
1.3 Research on cisplatin and oxaliplatin 
The elucidation of the molecular basis of the reduced mutagenicity and enhanced cytotoxicity of 
oxaliplatin in cisplatin-resistant tumors would make a significant contribution to the development of the 
third generation platinum drugs with greater efficacy and less toxicity. Extensive research and studies on 
cisplatin, oxaliplatin and their DNA adducts have been carried out. Recent interest has been focused on the 
interactions between their DNA adducts and cellular regulatory proteins vital for cellular repair and 
replication.  
 
1.3.1 Research methods 
Besides the in vivo and in vitro experiments, the study on molecular structure is another important 
direction. Only a few experimental structures of cisplatin-DNA or oxaliplatin-DNA adducts are currently 
available in the Research Collaboratory for Structural Bioinformatics (RCSB) data bank on line. These 
experimental structures have been solved either by x-ray crystallography or by nuclear magnetic resonance 
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(NMR) in various conditions. Reproducing these structures or comparing results is difficult.  
 
Molecular dynamics (MD) simulation is a special discipline of molecular modeling. One of its 
applications is actually used as an important tool in crystallography and NMR for structural determination 
and refinement. However, more significantly, just as its name implies, MD can be used to provide 
“dynamic” information, in other words, time-dependent properties of molecular system, which is not 
available from experimental structures. Therefore, in this thesis work, we decided to utilize molecular 
dynamics simulation to facilitate our study on cisplatin-DNA and oxaliplatin-DNA adducts. 
 
1.4 Molecular dynamics simulation 
Molecular dynamics computer simulation is most commonly used to simulate the dynamics of known 
structures. Conformational transitions and local vibrations are the usual subject of molecular dynamics 
studies.  
 
Molecular dynamics largely relies on numerically solving Newton’s equations of motion on an 
atomistic model of a molecular system to obtain the positions of each atom along a series of extremely 
small time steps in the order of femtoseconds (10-15). The resulting series of snapshots of molecular motion 
dynamics over time is called a simulation trajectory. Energy and other intermediate calculation results can 
be recorded along with the trajectory. Time-dependent properties and other valuable information can thus be 
derived from the trajectory. The initial coordinates of the molecular system generally come from the 
experimental structures and/or molecular modeling. The initial velocity of each atom is assigned randomly 
but normally following a Maxwell distribution. The velocities have to conform to the total kinetic energy of 
the system, which in turn, is dictated by the desired simulation temperature. It is achieved by slowly heating 
the system and then allowing the energy to equilibrate among the atoms. The details of how the position of 
an atom at the next time step is calculated from its current position and velocity are as follows. First, the 
energy has to be calculated using either classical mechanics or quantum mechanics methods. Classical 
mechanics are generally employed but limited to applications that do not involve drastic changes such as 
bond making or breaking. Quantum mechanics can be applied to study of dynamic processes involving 
chemical reactions but the energy calculation can be extremely difficult and time-consuming. Once the 
energy and current position are known, the forces can be calculated as the derivative of the energy with 
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respect to the change in position. With the derived force and known mass of the atom, the acceleration, 
velocity and position can be calculated sequentially. In detail, for example, the “leapfrog” algorithm, shown 
in Figure 1.3 is commonly used to numerically integrate Newton's second law in molecular dynamics 
simulations. For atom i at time t, time step Δt, velocity v and position r are successively updated every half 
of the time step. 
 
Figure 1.3 The Scheme of “Leapfrog” Algorithm.  
 
Another fundamental part of molecular dynamics is the so called force field. A force field refers to a 
group of equations and parameter sets used to describe the interactions among atoms within a molecular 
system. A force field can be empirical, semi-empirical or derived from quantum mechanics.  
 
Molecular dynamics does have its own limitations as well. As mentioned earlier, it is almost unfeasible 
to simulate dynamic processes involving chemical reactions. Besides theories and methods which are still 
far from perfection, the applications of molecular dynamics are often restricted by current computational 
power. The size of molecular system and length of simulation time must be designed carefully so that the 
calculation can finish within a useful time period, which restraints studies on multi- and macro- molecular 
systems and in a long and more physiologically relevant time scale. 
 
We decided to use AMBER (Assisted Model Building and Energy Refinement) software for our 
molecular dynamics simulations because AMBER is widely used for proteins and DNA. However, the force 
field parameters for Pt-GG adducts are not defined in AMBER and the currently available force field 
parameters for Pt-GG adducts are not robustly determined due to limitations in techniques and 
computational power of the time. Therefore we decided to recalculate the atomic partial charges of Pt-GG 
adducts using ab-initio method, which fully relies on quantum mechanics. Other force field parameters for 
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Pt-GG adducts were inherited from previous work.   
 
1.5 Thesis outline 
In chapter 2, I will describe my work on a comparison study of cisplatin-DNA and oxaliplatin-DNA 
adducts utilizing molecular dynamics simulation. Chapter 3 includes a general discussion and suggestions 
for future directions. 
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CHAPTER 2 THESIS WORK 
 
2.1 Introduction 
Since 1978, cis-diamminedichloroplatinum(II) (cisplatin, CP) has been the most widely used platinum 
(Pt) agent in chemotherapy as a treatment for certain cancers, such as testicular, ovarian, bladder, gullet 
(oesophagus), stomach, head, neck and non-small cell lung cancer. However, besides severe clinical side 
effects, such as nephrotoxicity and ototoxicity, the major limitations of CP are its cytotoxicity, mutagenicity, 
and the intrinsic or acquired resistance to CP in certain tumors. As a cisplatin analog, 
(trans-R,R)1,2-diaminocyclohexaneoxalatoplatinum(II) (oxaliplatin, OX) is the third most widely used 
platinum agent in chemotherapy. The FDA recently approved OX for the treatment of colorectal cancer and 
CP-resistant tumors. The clinical efficacy of CP and OX toward cancer cells is thought to result primarily 
from the formation of Pt-DNA adducts which prevent DNA replication and trigger a series of cell regulatory 
events that ultimately lead to cell death. We(13) and others(6 ;18) have found that CP and OX form the same 
types of adducts at the same sites on the DNA, although CP forms CP-DNA adducts with cis-diammine 
carrier ligand and OX forms OX-DNA adducts with (trans-R,R)1,2-diaminocyclohexane (DACH) carrier 
ligand. The major Pt-DNA adducts form as intrastrand-GG adducts which account for 60-65%. OX-DNA 
adducts have been reported to be less mutagenic in Ames test with S. typhimurium(7 ;9) and in human cell 
lines than CP-DNA adducts. The apparent clinical differences between CP and OX in their cytotoxicity, 
mutagenicity and efficacy in tumors are thought to be due to the differential recognition of CP-DNA and 
OX-DNA adducts by proteins involved in DNA damage-recognition and repair mechanisms. For example, 
some DNA damage-recognition proteins, especially those of the HMG-domain family, bind more tightly to 
CP-DNA adducts than to OX-DNA adducts(17 ;23); the DNA mismatch repair complexes hMSH2(5) and 
MutS(22) bind with greater affinity to CP-DNA adducts than to OX-DNA adducts; the DNA polymerases η 
and β both catalyze translesion synthesis bypassing OX-DNA adducts with higher efficiency than CP-DNA 
adducts(3). Here we hypothesize that the differential recognition of CP-DNA and OX-DNA adducts by a 
wide range of proteins involved in DNA damage-recognition and repair is due to the differences in 
conformation and/or conformational dynamics between CP-DNA and OX-DNA adducts. 
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The crystal structures of CP-DNA and OX-DNA adducts in the same dodecamer DNA sequence have 
been reported. The two structures were very similar except for the nature of the carrier ligand in the major 
groove and two potential hydrogen bonds between ligand and DNA. One hydrogen bond was reported to be 
between 5’ ammine NH3 ligand and the terminal oxygen atom of 5’ G* (the guanine coordinated to the 
platinum adduct) phosphate group in CP-DNA adduct(16). The other was between 3’ amine NH2 group of 
DACH ligand and the O6 atom of 3’ G* in OX-DNA adduct(15). There exist conformational differences 
between CP-DNA and OX-DNA adducts. However, the possible differences in their conformational 
dynamics have not been elucidated in previous studies. In addition, although considerable differences 
between Pt-DNA adducts and undamaged DNA have been reported, no previous studies have compared 
them under the same conditions in the same DNA sequence context. Here, in this study, we used molecular 
dynamics (MD) simulation to explore the differences in conformation and conformational dynamics 
between CP-DNA and OX-DNA adducts, and between Pt-DNA adducts and undamaged DNA, using the 
same DNA sequence context.  
 
The previously available atomic partial charges of CP-GG and OX-GG adducts were not rigorously 
determined due to the limitations of knowledge and computational power at the time. Therefore we 
recalculated these charges using well-accepted methods and the most updated quantum mechanics program 
Gaussian03. All the other force field parameters of CP-GG and OX-GG adducts were referenced, extended 
or modified based on AMBER parm99 force field parameters and previous work by Yao et al.(21), Scheeff 
et al(14). and Kozelka et al(4). The simulation protocol had been refined for Pt-DNA adducts. Altogether we 
did twenty-five 10 ns unrestrained and fully solvated MD simulations using AMBER v8.0. All twenty-five 
simulations reached equilibrium within 2 ns and therefore, the structures in the final 8 ns were used for 
conformation and conformational dynamics analysis. The equilibrium structures were independent of the 
initial conditions and were in good agreement with the NMR data. The geometry of Pt-GG adducts was 
intuitively reasonable. Our data derived from MD simulation trajectories showed greater distortion at the 5’ 
G* of both CP-GG and OX-GG adducts in agreement with previous NMR structures and MD simulation 
studies. Our data suggested that the differences between the 5’ and 3’ G* of Pt-GG addcuts might be due to 
the different flexibility of the phosphodiester bond connecting the 5’ and 3’ G*. Our data also showed 
several differences between CP-DNA and OX-DNA adducts, including the preferential orientation of the 
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platinum carrier ligand to the 5’ or 3’ side of the adduct and the frequency distributions of several DNA 
duplex helical parameters of the central four base pairs surrounding the platinum adduct. The differences in 
conformation and conformational dynamics may provide a biological explanation to the discrimination 
between CP-DNA and OX-DNA adducts by those specific DNA proteins. We postulate that CP-DNA 
adducts may adopt favorable conformations for binding DNA damage-recognition proteins, such as 
HMG-domain proteins and DNA mismatch repair complex more frequently than OX-DNA adducts; 
however, as for DNA polymerases η and β, it may be the other way around. Future NMR and MD studies 
are planned to test this hypothesis. 
 
2.2 Method 
 
2.2.1 Starting structures 
All five starting structures contained 12-mer DNA duplex in the same sequence context 
5’-d(CCTCAG*G*CCTCC)-3’. The NMR solution structures of CP-DNA adduct (data not published), 
OX-DNA adduct (1PGC.pdb(19)) and undamaged B-form DNA (B-DNA, data not published) solved in our 
lab were used as three starting structures. The other two starting structures were derived from the NMR 
solution structure of hSRYHMG complexed to DNA (1J46.pdb(12)) for the DNA backbone, the x-ray 
crystallography structure of CP·DNA·HMG complex (1KSB.pdb(10)) for the CP-GG adduct and our NMR 
solution structure of OX-DNA (1PGC.pdb) for the OX-GG adduct. In the molecular modeling program, we 
manually built these two starting structures, one CP-DNA adduct and one OX-DNA adduct, using insightII 
(Molecular Simulations Inc., San Diego). The original DNA sequence from 1J46.pdb was mutated to the 
same DNA sequence used for our NMR solution structures. The templating DNA backbone, which was 
more bent than the DNA in the NMR solution structures, provided a good test of whether our MD 
simulations were capable of driving very different starting structures to non-distinguishable structures when 
simulations reached equilibrium.  
 
2.2.2 Force field parameterization 
The force field parameters, including the atomic partial charges for CP-GG and OX-GG adducts are 
not defined in the standard AMBER force field library. However, they are required and crucial in MD 
simulations. In order to determine the atomic partial charges of CP-GG and OX-GG adducts, the 
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9-methyl-guanine derivatives cis-[Pt(NH3)2(9-Me-Guo)2]2+ (CP-meG2) and [Pt(DACH)(9-Me-Guo)2]2+ 
(OX-meG2) were used to simplify the calculation. These derivatives were manually built from our NMR 
solution structures by using insightII. Gaussian03 was employed to quantum mechanically optimize the 
geometry of these derivatives and to determine the partial charge on each atom. Density functional method 
B3LYP implemented within Gaussian03 was utilized; LanL2DZ basis set was used exclusively for the 
platinum atom and 6-31Gd basis set was used for the rest of the atoms. The atomic partial charges were 
determined using Mulliken method implemented within Gaussian03 based on either the structure geometry 
optimized by Gaussian03 or the NMR structure modified to the 9-methyl-guanine derivative. The Mulliken 
method turned out to be insensitive to the geometry of the structure and the resulting atomic partial charges 
were consistent in every geometry optimized or non-optimized structure. The partial charge of the platinum 
atom was close to the previously published value, while the partial charges of four nitrogen atoms 
surrounding the platinum atom were significantly different from the previously published values. The 
partial charges of the rest of the atoms were within the theoretical range and comparable with their 
counterparts in the standard force filed. The Mulliken charges based on the structure of the original 
9-methyl-guanine derivative modified from our NMR solution structure without further geometry 
optimization were used as the new atomic partial charges for Pt-GG adducts and incorporated into our force 
field parameters. The atomic partial charges of chemically equivalent atoms (such as the pseudo-equatorial 
hydrogen atoms of the ammine group, the corresponding atoms in the two guanine bases etc.) were 
averaged and the small charge discrepancy due to the structural difference between 9-methyl-guanine and 
deoxyguanine was distributed to the sugar according to the standard charge transfer technique used by Yao 
et al.(21). Besides the atomic partial charges, other force field parameters of Pt-GG adducts were referenced 
from AMBER parm99 force field parameters or from previous work by Yao et al.(21) and Scheeff et al.(14). 
 
2.2.3 MD simulation protocol 
The starting structures described earlier were first modified by removal of hydrogen atoms in insightII 
and were further prepared by LEaP module of AMBER v8.0. The Cornell et al. force field and parm99 
parameter set were used, as well as our self-defined force field parameters for Pt-GG adducts. The 
Generalized Born parameters were set to use modified Bondi radii (where the radius of hydrogen bonded to 
oxygen or sulfur was set to 0.8 Å; hydrogen bonded to carbon was 1.3 Å; hydrogen bonded to nitrogen was 
1.3 Å). The procedures for preparing structures for MD were as following. Firstly hydrogen atoms were 
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added back according to the nucleotide templates in AMBER force field library "all_nucleic94.lib". 
Secondly the structures were neutralized with counter-ions. 19, 20 and 22 sodium ions Na+ were added and 
placed by LEaP to the system of CP-DNA, OX-DNA and B-DNA respectively. Thirdly the neutralized 
system was fully solvated in a rectangular parallelepiped water box using default TIP3 model water 
molecules. The distance between the wall of the periodic box and the closest atom in the solute was set to 
be 12.5 Å. There were 7495, 7264 and 6957 water molecules added to the system of CP-DNA, OX-DNA 
and B-DNA respectively. This yielded a periodic cubic box with edge approximate 70 Å for the three 
systems.  
 
The whole system underwent 120 ps minimization and relaxation before a 10 ns production MD 
carried out by SANDER module of AMBER v8.0. The nonbonded cutoff was set to be 9.0 Å and the 
nonbonded list was updated every 10 steps. No Generalized Born term was used. The MD simulations were 
always carried out in NPT condition (constant pressure, using isotropic position scaling, at 1 atm (1 atm = 
6.9 kPa), pressure relaxation time constant 0.2 ps in relaxation MD and 2 ps in production MD; constant 
temperature, using weak-coupling algorithm, at 300 K, heat bath coupling time constant 0.2 ps in relaxation 
MD and 1 ps in production MD) with a 1 fs time step. In MD simulations, the SHAKE algorithm was 
applied to all bonds involving hydrogen atom and in turn the regular force evaluation omitted those bonds. 
The translational center-of-mass motion was removed every 1 ps. Every time the system was heated up, 
zero velocity information was inherited from the previous stage and a Maxwell distribution of velocities 
was re-established. In minimization and relaxation, a harmonic potential was applied to Pt-DNA adduct or 
DNA to restrain its motion. The restraint was gradually weakening and became zero at the final stage of 
relaxation. The following 10 ns production MD was carried out unrestrained.  
 
The detail of system minimization and relaxation was as follows. First, the whole system, including 
Pt-DNA adduct or DNA, water molecules and counter-ions, was minimized for 2000 steps of steepest 
descent (SD) in constant volume condition with a harmonic potential of 500 kcal/mol Å2 (1 cal = 4.184 J) 
applied to Pt-DNA or DNA to fix its conformation. Second, the system was heated up from 0 K to 300 K 
and kept in NVT (constant volume and constant temperature) condition with the harmonic restraints 
unchanged in a 20 ps relaxation MD. Third, the system was further relaxed in another short 20 ps MD in 
NPT condition with the same harmonic constraints. Fourth, the system was further minimized for 2000 
 14
steps of SD in constant volume condition three times, with a weakening harmonic potential of 500, 50 and 5 
kcal/mol Å2 respectively. Fifth, the system was heated up from 10 K to 300 K and kept in NVT condition 
with the harmonic restraints of 5 kcal/mol Å2 in a 20 ps relaxation MD. Sixth, four rounds of 20 ps 
relaxation MD were carried out in NPT condition with a further weakening harmonic potential of 5, 1, 0.1 
and 0 kcal/mol Å2 respectively. Seventh, the system was heated up from 10 K to 300 K in NVT condition 
with zero restraints in a 20 ps relaxation MD. Finally, the system was heated up for the very last time from 
100 K to 300 K at the beginning of 10 ns production MD. 
 
The above protocol was applied to every MD simulation. Other parameters unmentioned were set to 
default.  
 
2.2.4 MD simulations and trajectory analysis 
Twenty-five 10 ns unrestrained and fully solvated MD simulations were carried out by using SANDER 
module of AMBER v8.0. Five replicas for each of the five starting structures differed only in the MD initial 
velocity assigned when the system was heated up for the last time. The atomic coordinates of structures 
were saved every 1 ps. Both the 5’ and 3’ terminal base pairs were excluded from analysis because, in a few 
simulations, the terminal bases were not base-paired and in some extreme cases they were stacked with 
each other. Therefore only the central ten base pairs 5’-d(CTCAG*G*CCTC)-3’ were considered in 
trajectory analysis and the PTRAJ module of AMBER v8.0 was employed. 
 
2.2.5 Hydrogen bond occupancy 
A distance of less than 3.3 Å and an angle of greater than 135 ° between the potential hydrogen bond 
donor and acceptor were used as the criteria for a hydrogen bond formation. The occupancy of one 
hydrogen bond was defined as the percentage of frames in which the hydrogen bond existed. The hydrogen 
bond occupancy of one base pair was defined as the average occupancy of hydrogen bonds existing within 
this base pair. For example, the hydrogen bond occupancy of normal G·C base pair was the average 
occupancy of the three standard Watson-Crick hydrogen bonds. However, hydrogen bonds were formed 
between non-complementary bases in damaged DNA adducts because of the distortion and misalignment of 
bases. When calculating the hydrogen bond occupancy of base pairs, the occupancy of such a hydrogen 
bond of at least 5% was necessary for consideration and the occupancy was split evenly between two base 
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pairs. 
 
2.2.6 Inter-proton distance constraint comparison 
A set of inter-proton distance constraints was derived from the NMR data and these constraints were 
used to compute the NMR solution structures by CNS (Crystallography & NMR System) program(2). In 
CNS calculation, a distance violation was defined as one inter-proton distance of resulting structure 
deviated from the range of corresponding distance constraint by more than 0.5 Å. The same criterion was 
applied when we tried to evaluate how well our MD simulation structures agreed with the NMR data. In 
other words, for one inter-proton pair, if the average of trajectory derived distance was beyond its 
constraints by more than 0.5 Å, a distance violation was reported. In addition, we classified these 
constraints into several categories based on the locations of two protons. The two protons may be from the 
same nucleotide, from two nucleotides within the same strand (intrastrand) or from two nucleotides on 
different strands (interstrand). For one proton, it may be a base proton or a sugar pucker proton. The H1’ 
proton was treated as a base proton because its position is largely independent of sugar pucker. All the other 
protons of the sugar were considered as sugar pucker protons because their positions were strongly 
influenced by the sugar pucker conformation. Only the distance constrains of the central four base pairs 
5’-d(A5G*6G*7C8)-3’ were considered in this study. 
 
2.3 Results 
 
2.3.1 Stability of the MD simulations 
In order to determine how long it took for the simulations to reach equilibrium and in turn to decide 
the range of trajectories used for the following analysis, all-atom mass-weighted root-mean-square 
deviation (RMSD) referenced to the corresponding NMR structures were calculated over all twenty-five 
trajectories. Based on the plot of average RMSD over time (Figure 2.1), we concluded that all twenty-five 
simulations reached equilibrium within 2 ns. Therefore our data were derived from the trajectories from 2 
ns to 10 ns (final 8 ns) unless mentioned otherwise. The average RMSD was 2.73 ± 0.53 Å over all ten 
simulations of CP-DNA, 2.08 ± 0.43 Å over all ten simulations of OX-DNA, and 2.80 ± 0.30 Å over all 
five simulations of B-DNA. In addition, the curves of OX-DNA simulations were well separated from those 
of CP-DNA and B-DNA simulations; however, the curves of CP-DNA simulations were interlaced with 
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those of B-DNA simulations. The curves of all ten CP-DNA simulations were interlaced with one another 
within the final 8 ns. Thus the simulations actually converged to similar equilibrium structures no matter 
how different the starting structures and/or MD initial velocity were. Similar trends were observed for 
OX-DNA and B-DNA simulations. 
 
Figure 2.1 The average RMSD over time. <RMSD> at time t stands for the average of RMSD from time 
zero to time t. B-DNA, CP-NMR and OX-NMR stand for simulations starting from NMR solution 
structures. CP-CRY and OX-CRY stand for simulations starting from manually built more distorted 
structures. Five simulation replicas starting from the same structure but with different initial MD velocity 
are represented in solid line, dash line, dot line, dash-dot line and dash-dot-dot line respectively. 
 
2.3.2 MD simulations reproduced NMR-derived inter-proton distances 
In order to assess how well MD simulation structures agreed with corresponding NMR structure, we 
evaluated to what extent MD simulations reproduced NMR-derived inter-proton distances. There were 171, 
160 and 245 inter-proton distance constraints derived from NMR data within the central four base pairs 
5’-d(A5G*6G*7C8)-3’ of CP-DNA, OX-DNA adducts and B-DNA respectively. The number and detail of 
distance violations are listed in Tables 2.1 and 2.2 respectively. Most of the violations in CP-DNA 
simulation structures involved A5 and G*6 nucleotides, which were on the 5’ side of the adduct. Overall, 
there were 5 (< 3%), 2 (< 2%) and 10 (< 5%) violations for CP-DNA, OX-DNA adducts and B-DNA 
respectively. The very small number of violations compared to the total number of distance constraints 
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indicated that our MD simulations largely reproduced the NMR data. 
 
Table 2.1 The number of various violations. The very first and last columns give the total number of 
inter-proton distance constraints and the number of constrains in each category inter-strand, intra-strand and 
same nucleotide respectively. The middle columns give the number of violations between base and base 
protons or between base and sugar pucker protons, and the total number of violations in each category. 
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Table 2.2 The detail of violations. The above table lists the detail information about the inter-proton 
distance violations, showing the two protons involved in the violation, the experimental NOE inter-proton 
distance constraint range, the NOE range expended outwards by 0.5 Å and the simulation trajectory 
averaged inter-proton distance with standard deviation in parenthesis. 
 
As a control, we applied the same criterion to the top-15 lowest-energy NMR structures calculated 
from the CNS program. There were 0 (0%), 0 (0%) and 3 (< 2%) violations for CP-DNA, OX-DNA adducts 
and B-DNA respectively. The discrepancy in the number of distance violations between our AMBER 
simulation and CNS calculation were thought to primarily result from the fact that the AMBER simulation 
was under unrestrained and fully solvated condition, whereas the CNS calculation used the simulated 
annealing protocol in vacuum and was restrained by the inter-proton distance constraints. 
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2.3.3 Geometry of the platinum adducts 
 
Table 2.3 The platinum geometry. The upper panel illustrates the three kinds of platinum geometry we are 
interested in, the four N-Pt-N angles (N31 and N32 are two nitrogen atoms from the amine groups of the 
platinum ligand), the α angle (the angle between Pt-N7 bond and the plane of guanine ring) and 
displacement (the distance of the platinum atom from the plane of guanine ring), and the GG dihedral angle 
(the dihedral angle of the two guanine ring planes). The lower table lists the average and standard deviation 
of each geometry parameter from the 8 ns simulation trajectories and top-15 lowest energy NMR solution 
structures for cisplatin-DNA, oxaliplatin-DNA adducts and B-DNA respectively. 
 
The geometry parameters (shown and explained in Table 2.3) of platinum adducts derived from both 
simulation structures and NMR structures are listed in Table 2.3. There are some differences in the 
geometry of platinum adducts between CP-DNA and OX-DNA adducts based on the data derived from our 
NMR structures, such as the GG dihedral angle, the α angle and displacement of the platinum atom out of 
the guanine plane for both 5’ and 3’ guanines. However, all these differences are diminished in data derived 
from our simulation structures. For example, the α angles from the 5’ G* are 27.30 ± 2.92 º and 40.26 ± 
3.83 º for the NMR structures of CP-DNA and OX-DNA adducts respectively; whereas they are 21.73 ± 
7.23 º and 20.96 ± 8.69 º for the simulation structures of CP-DNA and OX-DNA adducts respectively, of 
which the difference of averages is much smaller than the sum of standard deviations.  
 
2.3.4 Hydrogen bonds 
In this work, we sought all possible hydrogen bonds through all potential hydrogen bond donors and 
acceptors, and we calculated the occupancy of all possible hydrogen bonds. We calculated the standard and 
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non-standard Watson-Crick hydrogen bond occupancy of each base pair for CP-DNA, OX-DNA adducts 
and B-DNA. The data are plotted in Figure 2.2. When compared to B-DNA, both CP-DNA and OX-DNA 
adducts show a significant decrease on standard Watson-Crick hydrogen bond occupancy in the 5’ G*6·C19 
base pair and a considerable decrease in the A5·T20 base pair on the 5’ side of the adduct, whereas the base 
pairs on the 3’ side of the adduct are almost completely intact. Meanwhile, a considerable increase on 
non-standard Watson-Crick hydrogen bond occupancy was found in the 5’ G*6·C19 base pair and 
noticeable increases in the 5’ A5·T20 and 3’ G*7·C18 base pairs as well, presumably compensating the loss 
of standard Watson-Crick hydrogen bonds. Two other hydrogen bonds with significantly high occupancy 
between the platinum carrier ligand and the DNA were identified and are shown in Figure 2.3. One is 
between the 3’ amine hydrogen of the platinum and the oxygen atom O6 of the 3’ G*7, with occupancy of 
21.4% and 53.5% for CP-DNA and OX-DNA adducts respectively. The other is between the 5’ amine 
hydrogen of the platinum and the nitrogen atom N7 of A5, with occupancy of 61.8% and 34.5% for 
CP-DNA and OX-DNA adducts respectively. The details of these hydrogen bonds with their occupancies 
are listed in Table 2.4.  
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Table 2.4 Hydrogen bond occupancy. The above table gives the detail information of hydrogen bond 
occupancy in three cases.  
 
Figure 2.2 Hydrogen bond occupancy of base pairs. The above plot illustrates the significant decreases in 
the standard Watson-Crick hydrogen bond occupancy and the significant increases in the abnormal 
hydrogen bond occupancy of base pair at the platinum crosslink lesion. The B-DNA, cisplatin-DNA and 
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oxaliplatin-DNA are in black, red and blue respectively. The standard Watson-Crick hydrogen bond 
occupancy of base pair and the abnormal hydrogen bond occupancy of base pair are in solid line and dash 
line respectively.  
 
Figure 2.3 Hydrogen bonds between platinum carrier ligand and DNA. Within the DNA which is in 
green, the pink part represents the N7 atom of A5 and the red part represents the O6 atom of G*7. The 
platinum adducts are mostly in red. The gray parts of the platinum adducts are the amine hydrogen atoms. 
The dash lines illustrate the potential hydrogen bonds between the platinum amine groups and the DNA 
bases. 
 
2.3.5 Torsion angles of the phosphodiester bond connecting the 5’ G*6 and 3’ G*7 
In order to evaluate the flexibility of the phosphodiester bond connecting the 5’ G*6 and 3’ G*7, we 
calculated the torsion angles on the 5’ side of G*7P (the phosphate atom between G*6 and G*7): 
G6C2'-G6C3'-G6O3'-G7P, G6C4'-G6C3'-G6O3'-G7P (epsilon, ε) and G6C3'-G6O3'-G7P-G7O5' (zeta, ζ), 
and on the 3’ side of G*7P: G6O3'-G7P-G7O5'-G7C5' (alpha, α), G7P-G7O5'-G7C5'-G7C4' (beta, β), 
G7O5'-G7C5'-G7C4'-G7C3' (gamma, γ) and G7O5'-G7C5'-G7C4'-G7O4' using the program CURVES 
v5.3(8). The frequency distributions of these torsion angles were used for comparison. The frequency 
distribution measured the probability of torsion angle ranging from -180 ° to +180 °. The frequency 
distributions of each torsion angle for CP-DNA, OX-DNA adducts and B-DNA are plotted together in red, 
green and blue respectively in Figure 2.4. 
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Figure 2.4 The frequency distributions of torsion angles of the phosphodiester bond. In each frequency 
distribution plot, the B-DNA, cisplatin-DNA and oxaliplatin-DNA are in blue, red and green respectively. 
The first row of frequency distributions are the three torsion angles from the 3’ side of the phosphodiester 
bond. The rest of the frequency distributions are the four torsion angles from the 5’ side of the 
phosphodiester bond. In the structure illustration, the atoms on the left side of P belong to the 5’ G*6 and 
the atoms on the right side of P including P belong to the 3’ G*7. 
 
Overall, for every torsion angle, the frequency distribution of B-DNA had one significant major peak 
and one much smaller secondary peak. The frequency distributions of CP-DNA and OX-DNA adducts were 
similar to each other. In addition, the frequency distribution of Pt-DNA adducts had only one major peak 
and lacked in the secondary peak. For all three torsion angles on the 5’ side of G*7P, the major peaks of 
Pt-DNA adducts were overlapped with the major peak of B-DNA. However, for the three out of four torsion 
angles on the 3’ side of G*7P, the major peaks of Pt-DNA adducts were overlapped with the secondary peak 
of B-DNA. As compared to B-DNA, in Pt-DNA adducts, the G7O5'-G7C5'-G7C4'-G7O4' torsion angle was 
shifted from around 72 ° to around -72 °; the γ torsion angle was shifted from around ±180 ° to around 36 °; 
and the β torsion angle was shifted from around 72 ° to around ±180 °.  
 
2.3.6 DNA conformational dynamics 
NMR and x-ray crystallography structures could provide us conformation but not conformational 
dynamics information, which is an intrinsic advantage of MD simulation. We could monitor the variations 
of selected parameters in a time-dependent fashion from the MD trajectory. In this work, we assessed the 
DNA conformational dynamics through the DNA duplex helical parameters because they could provide an 
accurate description of relative position between two complementary bases and between two adjacent bases 
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and base pairs. The helical parameters were calculated using the program CURVES v5.3. The frequency 
distributions of these helical parameters of the central four base pairs of undamaged B-DNA were used for 
comparison. The frequency distribution illustrated the probability of every conformation cluster explored in 
MD simulation and it could tell us which conformation was more preferred and which one was not. The 
frequency distributions of each helical parameter for CP-DNA, OX-DNA adducts and B-DNA are plotted 
together in red, green and blue respectively in Figures 2.5. 
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Figure 2.5 The DNA duplex helical parameters for the central four base pairs. The above figures first 
illustrate what are the base-base and base-pair-step helical parameters and then give the frequency 
distribution of each parameter for the central four base pairs. In each frequency distribution plot, the 
B-DNA, cisplatin-DNA and oxaliplatin-DNA are in blue, red and green respectively.  
 
When comparing both Pt-DNA adducts to B-DNA, several striking differences were identified, 
including buckle and propeller twist for the A5·T20 base pair, shear and propeller twist for the G*6·C19 
base pair, buckle and propeller twist for the G*7·C18 base pair; roll at the G*6·C19/G*7·C18 base pair step, 
and slide, tilt and roll at the G*7·C18/C8·G17 base pair step. These differences indicated that the 
conformational dynamics profile of B-DNA was alternated by the platinum adducts. 
 
When comparing CP-DNA to OX-DNA, some considerable differences were observed. For base-base 
helical parameters, noticeable differences were observed for propeller twist for the G*6·C19 and G*7·C18 
base pairs and buckle for the C8·G17 base pair. For base-pair-step helical parameters, shift and slide were 
different at all three base pair steps, particularly slide at the A5·T20/G*6·C19 and G*6·C19/G*7·C18 base 
pair steps and shift at the G*7·C18/C8·G17 base pair step. At the G*6·C19/G*7·C18 base pair step, the 
profiles of frequency distribution of roll were almost identical for CP-DNA and OX-DNA adducts, which 
was consistent with the GG dihedral angles for these two adducts. At the A5·T20/G*6·C19 base pair step, 
the profiles of frequency distribution of OX-DNA appeared to be relatively more spread out with a heavier 
tail on one side particularly for shift and twist compared to the CP-DNA adduct, which may imply that the 
OX-DNA adduct was more flexible between these two base pairs than the CP-DNA adduct. All of the above 
differences suggest that CP-DNA and OX-DNA differed in conformational dynamics. 
 
2.4 Discussion 
 
2.4.1 Accuracy of MD simulations 
We have developed the new partial charge parameters for CP-GG and OX-GG adducts. The new 
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partial charges on the platinum atom were similar to the previous published value. However, the new partial 
charges on the surrounding nitrogen atoms were significantly different. Therefore, it was important to 
validate the accuracy of our new partial charges in MD simulations. 
 
Our MD simulations did reasonably reproduce the NMR solution structures and our simulation 
structures did share some important geometry characteristics with the NMR solution structures. First, the 
simulation structures reached equilibrium within 2 ns. The equilibrium structures in the final 8 ns had the 
average RMSD around 3 Å with respect to the NMR solution structures and they were independent from 
the starting structures and MD initial velocities. Second, there were less than 5% violations of 
NMR-derived inter-proton distance constraints and the majority of these violations involved sugar pucker 
protons. Third, both CP-DNA and OX-DNA adducts in our MD simulations showed significantly increased 
roll angle at the G*6·C19/G*7·C18 base pair step and the GG dihedral angle with respect to the undamaged 
B-DNA. The square-planar platinum geometry and the 90 ° of the four N-Pt-N angles were well preserved. 
These geometry features were consistent with the experimental observations of Pt-DNA adducts. 
 
However, our MD simulations did not reproduce the differences between CP-DNA and OX-DNA 
adducts in the α angles and displacements of the platinum atom out of the 5’ and 3’ guanine planes, and the 
GG dihedral angle. The possible reasons were as follows.  
 
First, our new partial charges of CP-GG and OX-GG were similar to each other on the platinum atom 
and surrounding nitrogen atoms. The rest of the force field parameters and the protocol applied to the MD 
simulations were identical, which may lead to somewhat similar results from CP-DNA and OX-DNA 
simulations although their carrier ligands were structurally distinct from each other. However, we did 
observe quite a few conformation and conformational dynamics differences between CP-DNA and 
OX-DNA in our MD simulations. 
 
Second, the platinum geometry of our NMR solution structures was not derived directly from our 
NMR experimental data, but rather determined from CNS calculation. However, there were a few important 
differences between the CNS calculation and the AMBER MD simulation. The old partial charge 
parameters of Pt-GG were used in the CNS calculation whereas the AMBER simulation employed the new 
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parameters. The simulated annealing protocol used in the CNS calculation was in vacuum and restrained by 
NMR data, while the AMBER simulation was in fully solvated condition and unrestrained. What impacts 
these differences have on the final resulting structures are currently under investigation. 
 
2.4.2 The DNA duplex is more distorted on the 5’ side of the adduct than on the 3’ side 
Several authors have reported that the majority of the misinsertion mutations occurred opposite the 
5’G(1). In previous work, we have shown that DNA polymerase η and β both catalyzed translesion synthesis 
with higher efficiency in insertion of a dNTP opposite the 5’ G* than opposite the 3’G*(1 ;3). Marzilli and 
co-workers have illustrated a faster exchange rate between the water and imino proton of 5’ G*, and 
furthermore, an unusually large positive shift and slide at 5’ X/G* base pair step(10). Elizondo-Riojas and 
Kozelka, in their MD simulations, have shown greater mobility of 5’ G*·C base pair(4). All of these 
previous studies have indicated that the 5’ G*·C base pair was more flexible and more distorted than the 3’ 
G*·C base pair. In this work, we provide further evidences from our MD simulations to support this idea. 
 
First, there were more inter-proton distance violations found involving 5’ G*6·C19 base pair than 
involving 3’ G*7·C18 base pair, which may imply the abnormality of 5’ G*6·C19 base pair. Secondly most 
convincingly, there was a significantly greater decrease of occupancy of standard Watson-Crick hydrogen 
bonds within the 5’ G*6·C19 base pair than the 3’ G*7·C18 base pair. 
 
The DNA sequence context may play a role here since we had the two platinated G*·C base pairs 
sandwiched by different base pairs, A·T base pair on the 5’ side and C·G base pair on the 3’ side. The reason 
we chose this asymmetric “AG*G*C” sequence context was that “AGG” appeared to be the most 
mutagenic sequence context, and in addition, all of our previous experimental studies employed the DNA 
template in the “AG*G*C” sequence context. However, most structural and experimental evidences 
supporting the idea that the 5’ G*·C base pair was more distorted than the 3’ G*·C base pair were from 
DNA templates in symmetric sequence contexts. 
 
Although the two nucleotides coordinated to the platinum adduct were guanines and the geometry of 
Pt-GG appeared to be symmetric, the phosphodiester bond connecting the two guanines was in asymmetric 
geometry with respect to the phosphate atom. Therefore we hypothesized that the phosphodiester bond may 
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provide an explanation to the asymmetric distortion of Pt-DNA adducts. Currently we checked the torsion 
angles of the phosphodiester bond connecting 5’ G*6 and 3’ G*7. Since we had the MD simulations of 
undamaged B-DNA in the same sequence context with Pt-DNA adducts, we had a complete set of data for 
comparison between damaged and undamaged DNA, and between CP-DNA and OX-DNA adducts. In 
addition, as far as we know, this is the first attempt to correlate the phosphodiester bond with the 
asymmetric distortion of Pt-DNA adducts.  
 
From the comparison of frequency distribution of torsion angle, our most significant observation was 
that the three torsion angles in Pt-DNA adducts on the 3’ side of the phosphodiester bond between G*6 and 
G*7 were significantly different from those in B-DNA. These torsion angles in Pt-DNA adducts physically 
existed but were not preferred in undamaged B-DNA, while the torsion angles on the 5’ side of the 
phosphodiester bond in Pt-DNA adducts were similar to the predominant torsion angles in undamaged 
B-DNA. The significant torsion angle differences between Pt-DNA adducts and undamaged B-DNA on the 
3’ side of the phosphodiester bond may indicate that the 3’ side of the phosphodiester bond was more 
flexible than the 5’ side. Since the two coordinating guanines had to adapt an altered conformation to 
accommodate the conformational constraints imposed by the platinum adducts, the different flexibility of 
the phosphodiester bond on the 5’ side and 3’ side with respect to the phosphate may result in the distortion 
of the two guanines to a different extent. The more rigid 5’ side of the phosphodiester bond may cause the 
5’ G*6 to adapt a more severe distortion whereas the more flexible 3’ side of the phosphodiester bond may 
share part of the conformational constraints imposed on the 3’ G*7, resulting in less distortion of the 3’ G*7. 
Our data showed that the three torsion angles on the 3’ side of the phosphodiester bond were in unfavorable 
conformations for undamaged B-DNA, whereas the 3’ G*7 more or less was in a normal conformation, 
supporting the idea above. In addition, for all seven torsion angles, the frequency distributions for Pt-DNA 
adducts lacked the minor conformations observed for undamaged B-DNA, which may suggest that Pt-DNA 
adducts reduced the flexibility of the phosphodiester backbone on both sides. 
 
In order to further test our hypothesis that the more distorted base pairs on the 5’ side of the adduct 
may result from the flexibility of the phosphodiester bond, we plan to check the torsion angles of the rest of 
the phosphodiester bonds within the central four base pairs and the work is in progress.  
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In addition, from our MD simulations, most inter-proton distance violations involved the A5·T20 base pair 
and there was considerable decrease of occupancy of normal Watson-Crick hydrogen bonds within the 
A5·T20 base pair. The above two evidences were consistent with the experimental observation that 
extension from the Pt-DNA adduct was also strongly inhibited(11). 
 
2.4.3 Conformational differences between CP-DNA and OX-DNA adducts 
It has been reported that in the crystal structure of CP-DNA adduct, there was one hydrogen bond 
formed between the hydrogen atom of one of the two ammine NH3 ligands and a terminal oxygen atom of 
the 5’ G* 5’ phosphate group; and in the crystal structure of OX-DNA adduct, there was one hydrogen bond 
formed between the pseudo-equatorial hydrogen atom of the amine NH2 group of the DACH ligand cis to 
the 3’ G* and the oxygen atom O6 of the 3’ G* (N-O distance 2.9 Å; N-H···O angle 136 °). Thus it has been 
suggested that the cis-diammine carrier ligand of cisplatin was oriented more towards the 5’ side of the 
adduct and the (trans-R,R)1,2-diaminocyclohexane DACH carrier ligand of oxaliplatin was oriented more 
towards the 3’ side of the adduct.  
 
However, both hydrogen bonds have not been observed in NMR solution structures of either CP-DNA 
or OX-DNA adducts. Although our NMR data of OX-DNA adduct showed that the DACH ring was 
asymmetrically oriented, given the lack of downfield chemical shifts and broad line widths for the amino 
protons associated with DACH, we concluded that there was no hydrogen bond between the DACH ligand 
and DNA in our NMR solution structure of the OX-DNA adduct(19). But some have suggested that there 
might be hydrogen bond between the NH3 ligand and the O6 atom of the 3’G* in CP-DNA adduct(20).  
 
In this study, we did check the occupancy of these two hydrogen bonds for both CP-DNA and 
OX-DNA adducts. We found that the occupancy of the hydrogen bond reported in the crystal structure of 
CP-DNA adduct was less than 1% for both CP-DNA and OX-DNA adducts. Our data suggest that the 
formation of such a hydrogen bond is a rare event, and the crystal structure of CP-DNA adduct happened to 
capture this rare conformation, possibly due to crystal packing. In their work based on MD simulations of 
CP-DNA adduct, Elizondo-Riojas and Kozelka also reported that the formation of this hydrogen bond is a 
very rare event, unless one considers the possibility of hydrogen bonds bridged by one or two water 
molecules(4).  
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In this work, we did observe significant occupancy of the hydrogen bond formed between the 
hydrogen atom of the 3’ ammine NH3 ligand of CP or the 3’ amine NH2 group of DACH ligand of OX and 
the oxygen atom O6 in the purine base of the 3’ G*7, which had been previously reported in the crystal 
structure of OX-DNA adduct, but not CP-DNA adduct. The occupancy of this hydrogen bond was higher 
for OX-DNA adduct (53.5%) than CP-DNA adduct (21.4%). There was another significant hydrogen bond 
identified between the hydrogen atom of the 5’ ammine NH3 ligand of CP or the 5’ amine NH2 group of 
DACH ligand of OX cis to the 5’ G*6 and the nitrogen atom N7 in the purine base of A5. The occupancy of 
this hydrogen bond was higher for CP-DNA adduct (61.8%) than OX-DNA adduct (34.5%). It is interesting 
to note that the latter hydrogen bond was found on the 5’ side of the adduct and between 5’ NH3 or NH2 
group of ligand and N7 of A on the 5’ side of the adduct. An equilvalent hydrogen bond has been reported in 
MD simulations by Elizondo-Riojas and Kozelka except that the hydrogen bond was on the 3’ side of the 
adduct and between 3’ NH3 ligand of CP-DNA adduct and N7 of A on the 3’ side of the adduct(4). However, 
the DNA sequence context of their CP adduct was CG*G*A, which was in a reverse order of our AG*G*C, 
which may imply that the sequence context of Pt-DNA adducts could play a role in the determination of the 
conformation of Pt-DNA adducts. 
 
The differences in occupancy of hydrogen bonds between the ammine/amine hydrogen atoms of 
CP/OX and the bases on the 5’ and 3’ side of the Pt adducts suggest a difference in the orientation of Pt 
carrier ligands with respect to the DNA between CP-DNA and OX-DNA adducts. The cis-diammine carrier 
ligand of CP appears to be oriented more towards the 5’ side of the adduct and the 
(trans-R,R)1,2-diaminocyclohexane carrier ligand of OX appears to be oriented more towards the 3’ side of 
the adduct. Thus although from our MD simulations we did not observe the hydrogen bond reported in the 
crystal structure of CP-DNA adduct, our data are consistent with the observation reported by Lippard and 
colleagues with respect to the preferential orientation of carrier ligands of CP-DNA and OX-DNA adducts. 
 
2.4.4 Differences in conformational dynamics between CP-DNA and OX-DNA adducts 
From the comparison of frequency distribution of DNA duplex helical parameters, we did observe 
differences which may reflect the distinct conformational dynamics between CP-DNA and OX-DNA 
adducts. In addition, in this work we made a comparison with the undamaged B-DNA in the same sequence 
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context as the Pt-DNA adducts. Thus we could tell how the platinum adducts altered the conformational 
dynamic profile of B-DNA, such as roll angle at the G*6·C19/G*7·C18 base pair step. 
 
The DNA duplex helical parameters of which frequency distribution profiles were clearly different 
between CP-DNA and OX-DNA adducts were propeller twist and/or buckle for the central four base pairs, 
and shift and slide at central three base pair steps, presumably due to the different platinum adducts. The 
differences in frequency distribution profiles may indicate that in conformational space, for a given period 
of time, the percentage of time of CP-DNA adducts in one conformation is different from that of OX-DNA 
adducts in the equivalent conformation. If such conformation is critical for DNA damage-recognition 
proteins to bind or for DNA polymerases to bypass these adducts, our findings may provide a biological 
explanation for the differential recognition of CP-DNA and OX-DNA adducts by these proteins. Future 
NMR and MD studies are planned to further test this hypothesis. 
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CHAPTER 3 GENERAL DISCUSSION AND FUTURE DIRECTION 
 
In Chapter 1, I briefly introduced molecular dynamics simulation and in Chapter 2, I described in 
detail how we applied molecular dynamics simulation to study the conformation and conformational 
dynamics of cisplatin-DNA and oxaliplatin-DNA adducts. Data derived from the simulation trajectories 
showed that DNA duplexes containing either cisplatin or oxaliplatin adducts were more distorted on the 5’ 
side of the adduct than the 3’ side possibly due to the different flexibility of the phosphodiester bond on the 
5’ side and 3’ side. Based on the occupancy of hydrogen bonds between platinum ligand and DNA, cisplatin 
adduct appears to be oriented more towards the 5’ side of the adduct and oxaliplatin adduct more towards 
the 3’ side. Several differences were observed in conformational dynamics between cisplatin-DNA and 
oxaliplatin-DNA adducts from the frequency distributions of DNA duplex helical parameters. The 
information derived from simulation trajectories will help to clarify the discrepancies among the published 
experimental structures and to further elucidate the relationship between conformational dynamics 
differences and differential recognition by cellular DNA regulatory proteins.  
 
3.1 Limitations of experimental structure study 
In Table 3.1, I listed all the experimental structures currently deposited in RCSB data bank on line, 
which are either cisplatin or oxaliplatin intrastrand-GG adducts with double-stranded DNA. Apparently 
very few experimental structures are available, for example, only two for oxaliplatin-DNA adduct are 
deposited because it is not easy and could take a year or two to just obtain an acceptable structure. In 
addition, although these structures share some conformational features, such as the unwinding and bending 
of the DNA duplex at the lesion, there are significant discrepancies in the degree of unwinding and bending 
and in a number of important structural details. These discrepancies may appear to result from the different 
sequence context of DNA. However, the differences in experimental techniques, procedures, conditions and 
structural refinement methods of the time may be the primary causes. Therefore, fully reproducing 
previously obtained experimental structure or testing published results by resolving another experimental 
structure is difficult. However, molecular dynamics simulation has obvious advantages here.  
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Table 3.1 Experimental structures of Pt-DNA adducts. The above table lists all the experimental 
structures deposited in RCSB data bank on line by Jun 2006 which are either cisplatin (CP) or oxaliplatin 
(OX) intrastrand-GG adducts with double-stranded DNA. “CRY” stands for x-ray crystallography and 
“NMR” stands for nuclear magnetic resonance. 
 
3.2 Advantages of molecular dynamics study 
After all, molecular dynamics simulation is a series of computer programs. With current computational 
power, the simulations I described in detail in chapter 2 can finish within two weeks. In addition, the 
simulation results are always reproducible if running the same programs given the identical parameter 
settings. We could easily set up a series of simulations covering various conditions along with complete 
controls, which generally are not affordable by experiment. Therefore I propose to apply molecular 
dynamics simulation to a more comprehensive study of cisplatin-DNA and oxaliplatin-DNA adducts, 
aiming at not only comparison study between the two Pt-DNA adducts but also clarification of those 
discrepancies among the published experimental structures. 
 
3.3 Design of DNA sequence context 
The first thing to do is to design the sequence context of DNA duplex. We are still going to focus our 
study on intrastrand-GG adducts. From the previous studies, the two G*·C base pairs and the base pair 
immediately adjacent to them on the 5’ and 3’ side are most affected by the adducts. The rest of the flanking 
base pairs on both sides are relatively unaffected. Thus the variation of DNA sequence is restricted within 
the central four base pairs 5’-d(XG*G*Y)-3’. Since the asymmetric distortion of the DNA on the 5’ and 3’ 
side of the adduct is one of the discrepancies, we do not want to introduce the factor which may lead to the 
asymmetric distortion by sandwiching the two G*·C base pairs with different base pairs on the 5’ and 3’ 
side. Therefore, the central two G*·C base pairs are going to be symmetrically sandwiched by the identical 
base pair and the sequence context of the central four base pairs can be 5’-d(AG*G*A)-3’, 
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5’-d(TG*G*T)-3’, 5’-d(CG*G*C)-3’ and 5’-d(GG*G*G)-3’. The sequences of the rest of the flanking base 
pairs on both sides are also symmetrically designed to be 5’-d(CCTC)-3’ on the 5’ side and 5’-d(CTCC)-3’ 
on the 3’ side, which are the most commonly used sequence contexts in the published experimental 
structures. One example of the entire dodecamer sequence will be 5’-d(CCTCAG*G*ACTCC)-3’.  
 
3.4 Molecular dynamics simulation 
Once the sequence context of DNA duplex is determined, we are going to build an ideal B-DNA in 
straight form and coordinate cisplatin or oxaliplatin adducts to the central two G* at N7 atom using 
molecular modeling program. The reason we do not use experimental structures as a starting point is that 
there are no experimental structure available for some of our designed DNA sequences. In addition, in these 
molecular modeling structures, the N7-Pt-N7 angle, GG dihedral angle and some other platinum geometry 
parameters are expected to deviate from the experimental and theoretical values significantly since the DNA 
template is in ideal straight form. Thus once again we will challenge our force field parameters to overcome 
the distortion of starting structure and produce the intrinsic conformational characteristics of Pt-DNA 
adducts when simulations reach equilibrium. For each of our designed DNA sequence, three starting 
structures, one cisplatin-DNA adduct, one oxaliplatin-DNA adduct and one undamaged B-DNA as control 
will be used. As for the simulation protocol, we plan to further refine the minimization and relaxation 
procedures. The scripts for production runs will be modified when necessary. As for the simulation duration 
and number of simulation replicas, from our previous experience, the molecular system with similar size 
using similar simulation protocol reached equilibrium within 2 ns and therefore 5 ns should be long enough. 
Five or more replicas to provide enough sampling in conformational space may be a better strategy than a 
long simulation since a simulation may degrade in a long run.  
 
3.5 Simulation trajectory analysis 
Our molecular dynamics simulation goal is to study the possibly significant differences in 
conformation and conformational dynamics between cisplatin-DNA and oxaliplatin-DNA adducts in 
various sequence contexts, and meanwhile to clarify some discrepancies among the published experimental 
structures of these adducts. Both conformation and conformational dynamics information can be derived 
from the simulation trajectory. The trajectory is nothing but a time series of structures. We could derive 
conformational parameters from any individual frame of the trajectory or the averages of those 
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conformational parameters from the partial or entire trajectory. Since the frames of the trajectory are in 
time-dependent order, we could monitor the variations or dynamic changes of those conformational 
parameters over time, which is so called conformational dynamics. With the enormous amount of 
conformational dynamics data, various mathematical and statistical methods could be applied to reveal 
embedded information, such as histogram analysis which could reveal the frequency distribution of 
conformational species, principal component analysis which could reveal the dominant ones from multiple 
parameters, and cross-correlation analysis which could reveal the underlying relationships among 
parameters, etc. From our previous experience, we will have to find methods to be able to quantitatively 
evaluate and describe the differences. 
 
3.6 Conformational parameters and interactions we are interested in 
For every conformational parameter of the structure, we could derive its conformational dynamics 
counterpart. The conformational parameters we are going to investigate can be roughly divided into the 
platinum parameters and the DNA parameters.  
 
The platinum parameters are as follows. First the four N-Pt-N angles, the four N-Pt bond lengths and 
the planarity which evaluates to what extent the platinum atom and four surrounding nitrogen atoms are in 
the same plane are worth investigating since these parameters govern the square-planar geometry of 
platinum which should not be violated in any situation. The detail conformation of the diaminocyclohexane 
ring of the oxaliplatin adduct is worthy of interest as well, such as bond angles, bond lengths, torsion angles, 
whether or not the ring is in a chair conformation and so on. The GG dihedral angle, the α angle and 
displacement of the platinum atom out of the guanine plane for both the 5’ and 3’ guanines, the torsion 
angle (C8-N7-Pt-cisN) from both the 5’ and 3’ guanines are also in the list. Theoretically, when the cisplatin 
or oxaliplatin adduct is coordinated with two guanosines, the platinum atom is in an ideal square-planar 
geometry, the diaminocyclohexane ring of the oxaliplatin adduct is in an ideal chair conformation, the GG 
dihedral angle is 90 º, and the α angle and displacement are 0 º and 0 Å respectively for both the 5’ and 3’ 
guanines etc. However, in our molecular dynamics simulations, the cisplatin-GG and oxaliplatin-GG are in 
DNA dodecamer duplex. We would expect the platinum square-planar geometry and the chair conformation 
of the diaminocyclohexane ring of the oxaliplatin adduct to be well preserved and we would predict a 
significant deviations in the GG dihedral angle, the α angles and displacements, and the torsion angles from 
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their theoretic values. These deviations describe the distortion of the platinum geometry in DNA duplex.  
 
The DNA parameters basically include all the parameters which could be used to describe the 
conformation of a DNA duplex. Partial unwinding and significant bending at the Pt-GG crosslinking lesion 
are well recognized. But to what extent the DNA duplex is unwound and bent and the direction of DNA 
bend are not consistent among the published experimental structures. Thus they are worth further 
investigation. There are also some discrepancies in the sugar pucker conformation of the two guanine 
nucleotides coordinated to the platinum atom, the width and depth of the minor and major groove of the 
DNA duplex at the lesion. These geometry characteristics may imply that the normal B-like DNA duplex 
partially transforms to the A-like DNA duplex at the site of the adduct. Thus all key parameters which could 
be used to distinguish A-like and B-like DNA duplexes are under investigation. The platinum adduct 
coordinated to the two guanine rings at the major groove side of the DNA duplex, resulting in a 
head-to-head coordination of the two guanine rings, affects the DNA duplex helical parameters of the two 
guanine nucleic acid bases, as well as the two G*·C base pairs and immediately adjacent base pairs. Thus 
the DNA duplex helical parameters are of interest. In our current work described in Chapter 2 we found the 
asymmetric flexibility of the phosphodiester bond connecting the two guanine deoxynucleosides 
coordinated to the platinum adduct. We would like to expand our investigation to the rest of phosphodiester 
bonds within the central four base pairs. The torsion angles of the sugar pucker and glycosyl bond are under 
investigation too, especially the torsion angle of the glycosyl bond, which describes the relative position 
between the sugar pucker and the nucleic acid base. In our current work, we have already found that there 
was significant difference between the frequency distributions of the torsion angle of the glycosyl bond in 
the 5’ and 3’ guanine nucleotides (Figure 3.1). 
 
Figure 3.1 The frequency distributions of the torsion angle of the glycosyl bond in the 5’ and 3’ G*. 
The B-DNA, cisplatin-DNA and oxaliplatin-DNA are in blue, red and green respectively. 
 
We would also like to characterize all short and long range interactions, including hydrogen bonding, 
between DNA duplex and platinum adducts, and between solvent molecules and DNA adducts, since these 
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interactions may be the underlying forces governing the conformation and conformational dynamics.  
 
3.7 Molecular dynamics study on Pt-DNA adducts complex with various DNA regulatory proteins 
The next stage of our work is to apply molecular dynamics simulation to study the interactions 
between Pt-DNA adducts and DNA regulatory proteins, such as HMG-domain proteins and DNA 
polymerase β. Since the molecular system of Pt-DNA-Protein complex in fully solvated condition may be 
too big to reach equilibrium within a useful time period, minimization, relaxation and a short production run 
will be enough to reduce the initial artifacts or unfavorable interactions to an acceptable extent. We will use 
experimental structures of such Pt-DNA-Protein complexes, if available, as starting structures. We could 
also rely on molecular modeling, especially when we want to study Pt-DNA-Protein complexes in various 
DNA sequence contexts. As to molecular modeling, I propose to start from the equilibrium structures of 
Pt-DNA adducts obtained from previous stage simulations. We could attempt to dock these Pt-DNA adducts 
to the protein or vice versa based on the experimental evidences of such protein binding with DNA. We will 
definitely come up more than one Pt-DNA-Protein complex, which will be evaluated with molecular 
dynamics simulation until we gain faithful structures for further analysis and comparison. Similar 
conformation and conformational dynamics studies will be applied to the entire molecular system, including 
the protein. More importantly, we will characterize the significant interactions between the DNA adduct and 
the protein because these interactions may provide explanations of their biological properties. Based on 
molecular dynamics simulation results, we are going to generate hypothesizes and test them with biological 
experiments.  
 
3.8 Future studies 
We believe, eventually, molecular dynamics simulation will help us not only to clarify the 
discrepancies among the published experimental structures, but also to elucidate the biological differences 
between cisplatin and oxaliplatin adducts with DNA, ultimately contributing to the design of more effective 
anticancer drugs. 
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APPENDIX A  PT-GG FORCE FIELD PARAMETERS 
 
A.1 PT-GG.prep (for cisplatin-DNA simulation) 
 
    1    0    2 
db94.dat 
modified D-GUANOSINE - with 5' - phosphate group and 3' - O(minus) - N7 replaced by NB1 (atom type 
NB replaced by NR) 
 
 DG1  INT     1 
 CORR OMIT DU   BEG 
   0.0 
   1   DUMM  DU    M    0  -1  -2    0.00      0.00      0.00       0.0000 
   2   DUMM  DU    M    1   0  -1    1.00      0.00      0.00       0.0000 
   3   DUMM  DU    M    2   1   0    1.00     90.00      0.00       0.0000 
   4   P     P     M    3   2   1    1.60    119.04    200.00       1.1659 
   5   O1P   O2    E    4   3   2    1.48    109.61    150.00      -0.7761 
   6   O2P   O2    E    4   3   2    1.48    109.58     20.00      -0.7761 
   7   O5'   OS    M    4   3   2    1.60    101.43    -98.89      -0.4954 
   8   C5'   CT    M    7   4   3    1.44    119.00    -39.22      -0.0069 
   9   H5'1  H1    E    8   7   4    1.09    109.50     60.00       0.0754 
  10   H5'2  H1    E    8   7   4    1.09    109.50    -60.00       0.0754 
  11   C4'   CT    M    8   7   4    1.52    110.00    180.00       0.1720 
  12   H4'   H1    E   11   8   7    1.09    109.50   -200.00       0.1176 
  13   O4'   OS    S   11   8   7    1.46    108.86    -86.31      -0.3418 
  14   C1'   CT    B   13  11   8    1.42    110.04    105.60       0.1268 
  15   H1'   H2    E   14  13  11    1.09    109.50   -240.00       0.2019 
  16   N9    N*    S   14  13  11    1.49    108.06   -127.70      -0.4269 
  17   C8    CK    B   16  14  13    1.38    129.20     81.59       0.2334 
  18   H8    H5    E   17  16  14    1.08    120.00      0.00       0.2173 
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  19   NB1   NR    S   17  16  14    1.31    114.00   -179.90      -0.6196 
  20   C5    CB    S   19  17  16    1.39    103.90      0.00       0.1126 
  21   C6    C     B   20  19  17    1.42    130.40    180.00       0.5607 
  22   O6    O     E   21  20  19    1.23    128.80      0.00      -0.4486 
  23   N1    NA    B   21  20  19    1.40    111.38    180.00      -0.6591 
  24   H1    H     E   23  21  20    1.00    117.36    179.90       0.3696 
  25   C2    CA    B   23  21  20    1.38    125.24     -0.10       0.7118 
  26   N2    N2    B   25  23  21    1.34    116.02    180.00      -0.7661 
  27   H21   H     E   26  25  23    1.01    127.00     -0.82       0.3853 
  28   H22   H     E   26  25  23    1.01    116.53   -179.44       0.3853 
  29   N3    NC    S   25  23  21    1.33    123.30      0.00      -0.4848 
  30   C4    CB    E   29  25  23    1.36    112.20      0.00       0.4666 
  31   C3'   CT    M   11   8   7    1.53    115.78   -329.11       0.0804 
  32   H3'   H1    E   31  11   8    1.09    109.50     30.00       0.0985 
  33   C2'   CT    B   31  11   8    1.53    102.80    -86.30      -0.0581 
  34   H2'1  HC    E   33  31  11    1.09    109.50    120.00       0.0809 
  35   H2'2  HC    E   33  31  11    1.09    109.50    240.00       0.0809 
  36   O3'   OS    M   31  11   8    1.42    116.52   -203.47      -0.5232 
   
IMPROPER 
 C8   C4   N9   C1' 
 C5   N1   C6   O6 
 C6   C2   N1   H1 
 C2   H21  N2   H22  
 NB1  N9   C8   H8 
 N1   N3   C2   N2 
 
LOOP CLOSING EXPLICIT 
 C1'  C2' 
 C4   C5 
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 C4   N9 
 
DONE 
modified D-GUANOSINE - with 5' - phosphate group and 3' - O(minus) group - N7 replaced by NB2 (atom 
type replaced by NS) 
 
 DG2  INT     1 
 CORR OMIT DU   BEG 
   0.0 
   1   DUMM  DU    M    0  -1  -2    0.00      0.00      0.00       0.0000 
   2   DUMM  DU    M    1   0  -1    1.00      0.00      0.00       0.0000 
   3   DUMM  DU    M    2   1   0    1.00     90.00      0.00       0.0000 
   4   P     P     M    3   2   1    1.60    119.04    200.00       1.1659 
   5   O1P   O2    E    4   3   2    1.48    109.61    150.00      -0.7761 
   6   O2P   O2    E    4   3   2    1.48    109.58     20.00      -0.7761 
   7   O5'   OS    M    4   3   2    1.60    101.43    -98.89      -0.4954 
   8   C5'   CT    M    7   4   3    1.44    119.00    -39.22      -0.0069 
   9   H5'1  H1    E    8   7   4    1.09    109.50     60.00       0.0754 
  10   H5'2  H1    E    8   7   4    1.09    109.50    -60.00       0.0754 
  11   C4'   CT    M    8   7   4    1.52    110.00    180.00       0.1720 
  12   H4'   H1    E   11   8   7    1.09    109.50   -200.00       0.1176 
  13   O4'   OS    S   11   8   7    1.46    108.86    -86.31      -0.3418 
  14   C1'   CT    B   13  11   8    1.42    110.04    105.60       0.1268 
  15   H1'   H2    E   14  13  11    1.09    109.50   -240.00       0.2019 
  16   N9    N*    S   14  13  11    1.49    108.06   -127.70      -0.4269 
  17   C8    CK    B   16  14  13    1.38    129.20     81.59       0.2334 
  18   H8    H5    E   17  16  14    1.08    120.00      0.00       0.2173 
  19   NB2   NS    S   17  16  14    1.31    114.00   -179.90      -0.6196 
  20   C5    CB    S   19  17  16    1.39    103.90      0.00       0.1126 
  21   C6    C     B   20  19  17    1.42    130.40    180.00       0.5607 
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  22   O6    O     E   21  20  19    1.23    128.80      0.00      -0.4486 
  23   N1    NA    B   21  20  19    1.40    111.38    180.00      -0.6591 
  24   H1    H     E   23  21  20    1.00    117.36    179.90       0.3696 
  25   C2    CA    B   23  21  20    1.38    125.24     -0.10       0.7118 
  26   N2    N2    B   25  23  21    1.34    116.02    180.00      -0.7661 
  27   H21   H     E   26  25  23    1.01    127.00     -0.82       0.3853 
  28   H22   H     E   26  25  23    1.01    116.53   -179.44       0.3853 
  29   N3    NC    S   25  23  21    1.33    123.30      0.00      -0.4848 
  30   C4    CB    E   29  25  23    1.36    112.20      0.00       0.4666 
  31   C3'   CT    M   11   8   7    1.53    115.78   -329.11       0.0804 
  32   H3'   H1    E   31  11   8    1.09    109.50     30.00       0.0985 
  33   C2'   CT    B   31  11   8    1.53    102.80    -86.30      -0.0581 
  34   H2'1  HC    E   33  31  11    1.09    109.50    120.00       0.0809 
  35   H2'2  HC    E   33  31  11    1.09    109.50    240.00       0.0809 
  36   O3'   OS    M   31  11   8    1.42    116.52   -203.47      -0.5232 
   
IMPROPER 
 C8   C4   N9   C1' 
 C5   N1   C6   O6 
 C6   C2   N1   H1 
 C2   H21  N2   H22  
 NB2  N9   C8   H8 
 N1   N3   C2   N2 
 
LOOP CLOSING EXPLICIT 
 C1'  C2' 
 C4   C5 
 C4   N9 
 
DONE 
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CISPLATIN, (M=Main, S=Side chain dual, B=Side chain trigonal, 3=Side chain tetrahedral, E=End) 
 
 PTC  INT     1 
 CORR OMIT DU   BEG 
   0.0 
   1   DUMM  DU    M    0  -1  -2    0.00      0.00      0.00       0.0000 
   2   DUMM  DU    M    1   0  -1    1.00      0.00      0.00       0.0000 
   3   DUMM  DU    M    2   1   0    1.00     90.00      0.00       0.0000 
   4   PT    PT    M    3   2   1    2.01    127.95    180.00       0.7274 
   5   N32   N5    3    4   3   2    2.03     90.00    180.00      -0.9656 
   6   H321  H     E    5   4   3    1.01    109.47     60.00       0.4224 
   7   H322  H     E    5   4   3    1.01    109.47    180.00       0.4224 
   8   H323  H     E    5   4   3    1.01    109.47    300.00       0.4224 
   9   N31   N4    3    4   3   2    2.03    180.00     70.00      -0.9656 
  10   H311  H     E    9   4   3    1.01    109.47     60.00       0.4224 
  11   H312  H     E    9   4   3    1.01    109.47    180.00       0.4224 
  12   H313  H     E    9   4   3    1.01    109.47    300.00       0.4224 
 
DONE 
OXALIPLATIN, (M=Main, S=Side chain dual, B=Side chain trigonal, 3=Side chain tetrahedral, E=End) 
 
 PTX  INT     1 
 CORR OMIT DU   BEG 
   0.0 
   1   DUMM  DU    M    0  -1  -2    0.00      0.00      0.00       0.0000 
   2   DUMM  DU    M    1   0  -1    1.00      0.00      0.00       0.0000 
   3   DUMM  DU    M    2   1   0    1.00     90.00      0.00       0.0000 
   4   PT    PT    M    3   2   1    2.01    127.95    180.00       0.6889 
   5   N32   N5    3    4   3   2    2.03     90.00     90.00      -0.8412 
   6   H321  H     E    5   4   3    1.01    109.47     60.00       0.4119 
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   7   H322  H     E    5   4   3    1.01    109.47    300.00       0.4119 
   8   C1    CT    B    5   4   3    1.449   109.47    180.00       0.0273 
   9   HC11  H1    E    8   5   4    1.090   109.47    -75.23       0.1795 
  10   C2    CT    3    8   5   4    1.526   109.47    163.78      -0.2881 
  11   HC21  HC    E   10   8   5    1.090   109.47    300.00       0.1795 
  12   HC22  HC    E   10   8   5    1.090   109.47     60.00       0.1795 
  13   C3    CT    3   10   8   5    1.526   109.47    180.00      -0.2881 
  14   HC31  HC    E   13  10   8    1.090   109.47    300.00       0.1795 
  15   HC32  HC    E   13  10   8    1.090   109.47    180.00       0.1795 
  16   C4    CT    3   13  10   8    1.526   109.47     60.00      -0.2881 
  17   HC41  HC    E   16  13  10    1.090   109.47     60.00       0.1795 
  18   HC42  HC    E   16  13  10    1.090   109.47    180.00       0.1795 
  19   C5    CT    3   16  13  10    1.526   109.47    300.00      -0.2881 
  20   HC51  HC    E   19  16  13    1.090   109.47    180.00       0.1795 
  21   HC52  HC    E   19  16  13    1.090   109.47    300.00       0.1795 
  22   C6    CT    S   19  16  13    1.526   109.47     60.00       0.0273 
  23   HC61  H1    E   22  19  16    1.090   109.47     60.00       0.1795 
  24   N31   N4    3    4   3   2    2.03    163.45     27.15      -0.8412 
  25   H311  H     E   24   4   3    1.01    109.47    -71.57       0.4119 
  26   H312  H     E   24   4   3    1.01    109.47    168.53       0.4119 
 
LOOP CLOSING EXPLICIT 
 C6   N31 
 C6   C1 
 
DONE 
STOP 
 
Cisplatin-GG 
Guanine (G) Atom Name AMBER OLD NEW 
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4  P 1.1659 1.1659 1.1659 
5  O1P -0.7761 -0.7761 -0.7761 
6  O2P -0.7761 -0.7761 -0.7761 
7  O5' -0.4954 -0.4954 -0.4954 
8  C5' -0.0069 -0.0069 -0.0069 
9  H5'1 0.0754 0.0754 0.0754 
10  H5'2 0.0754 0.0754 0.0754 
11  C4' 0.1629 0.1629 0.1720 
12  H4' 0.1176 0.1176 0.1176 
13  O4' -0.3691 -0.3691 -0.3418 
14  C1' 0.0358 0.0358 0.1268 
15  H1' 0.1746 0.1746 0.2019 
16  N9 0.0577 0.0807 -0.4269 
17  C8 0.0736 0.2466 0.2334 
18  H8 0.1997 0.1187 0.2173 
19  NB1 -0.5725 -0.3435 -0.6196 
20  C5 0.1991 0.2681 0.1126 
21  C6 0.4918 0.5148 0.5607 
22  O6 -0.5699 -0.5699 -0.4486 
23  N1 -0.5053 -0.5053 -0.6591 
24  H1 0.3520 0.3520 0.3696 
25  C2 0.7432 0.7432 0.7118 
26  N2 -0.9230 -0.9230 -0.7661 
27  H21 0.4235 0.4235 0.3853 
28  H22 0.4235 0.4235 0.3853 
29  N3 -0.6636 -0.6636 -0.4848 
30  C4 0.1814 0.2044 0.4666 
31  C3' 0.0713 0.0713 0.0804 
32  H3' 0.0985 0.0985 0.0985 
33  C2' -0.0854 -0.0854 -0.0581 
34  H2'1 0.0718 0.0718 0.0809 
35  H2'2 0.0718 0.0718 0.0809 
36  O3' -0.5232 -0.5232 -0.5232 
Cisplatin Atom Name   OLD NEW 
4  PT 0.7090 0.7274 
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5  N32 -0.6480 -0.9656 
6  H321 0.2780 0.4224 
7  H322 0.2780 0.4224 
8  H323 0.2780 0.4224 
9  N31 -0.6480 -0.9656 
10  H311 0.2780 0.4224 
11  H312 0.2780 0.4224 
12  H313 0.2780 0.4224 
Oxaliplatin-GG 
Guanine (G) Atom Name AMBER OLD NEW 
4  P 1.1659 1.1659 1.1659 
5  O1P -0.7761 -0.7761 -0.7761 
6  O2P -0.7761 -0.7761 -0.7761 
7  O5' -0.4954 -0.4954 -0.4954 
8  C5' -0.0069 -0.0069 -0.0069 
9  H5'1 0.0754 0.0754 0.0754 
10  H5'2 0.0754 0.0754 0.0754 
11  C4' 0.1629 0.1629 0.1717 
12  H4' 0.1176 0.1176 0.1176 
13  O4' -0.3691 -0.3691 -0.3427 
14  C1' 0.0358 0.0358 0.1238 
15  H1' 0.1746 0.1746 0.2010 
16  N9 0.0577 0.0807 -0.4283 
17  C8 0.0736 0.2466 0.2291 
18  H8 0.1997 0.1187 0.2137 
19  NB1 -0.5725 -0.3435 -0.5982 
20  C5 0.1991 0.2681 0.1122 
21  C6 0.4918 0.5148 0.5590 
22  O6 -0.5699 -0.5699 -0.4455 
23  N1 -0.5053 -0.5053 -0.6599 
24  H1 0.3520 0.3520 0.3670 
25  C2 0.7432 0.7432 0.7079 
26  N2 -0.9230 -0.9230 -0.7649 
27  H21 0.4235 0.4235 0.3829 
28  H22 0.4235 0.4235 0.3829 
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29  N3 -0.6636 -0.6636 -0.4856 
30  C4 0.1814 0.2044 0.4605 
31  C3' 0.0713 0.0713 0.0801 
32  H3' 0.0985 0.0985 0.0985 
33  C2' -0.0854 -0.0854 -0.0590 
34  H2'1 0.0718 0.0718 0.0806 
35  H2'2 0.0718 0.0718 0.0806 
36  O3' -0.5232 -0.5232 -0.5232 
Oxaliplatin Atom Name   OLD NEW 
4 PT 0.7090 0.6889 
5 N32 -0.6980 -0.8412 
6 H321 0.2780 0.4119 
7 H322 0.2780 0.4119 
8 C1 0.2620 0.0273 
9 HC11 0.0660 0.1795 
10 C2 -0.1320 -0.2881 
11 HC21 0.0660 0.1795 
12 HC22 0.0660 0.1795 
13 C3 -0.1320 -0.2881 
14 HC31 0.0660 0.1795 
15 HC32 0.0660 0.1795 
16 C4 -0.1320 -0.2881 
17 HC41 0.0660 0.1795 
18 HC42 0.0660 0.1795 
19 C5 -0.1320 -0.2881 
20 HC51 0.0660 0.1795 
21 HC52 0.0660 0.1795 
22 C6 0.2620 0.0273 
23 HC61 0.0660 0.1795 
24 N31 -0.6980 -0.8412 
25 H311 0.2780 0.4119 
26 H312 0.2780 0.4119 
 
Table A.1 Atomic partial charges of CP-GG and OX-GG adducts. The above table lists atomic partial 
charge of every atom of cisplatin-GG and oxaliplatin-GG adducts. The charges of chemical-equivalent 
atoms are the same and thus the charges on two guanines are identical. The old charges were developed by 
Yao et al. and Scheeff et al. The new charges were developed in this thesis work. The unit of charge is an 
electron unit (1.602×10-19C) 
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A.2 frcmod.PT 
 
MASS 
PT  195.08                           Platinum atom 
NR  14.01        0.530               sp2 N N7 of DG1 bound to PT, parm99 values for NB 
NS  14.01        0.530               sp2 N N7 of DG2 bound to PT, parm99 values for NB 
N4  14.01        0.530               sp3 N PT bound ligand nitrogen, trans to NR, parm99 values 
for N3 
N5  14.01        0.530               sp3 N PT bound ligand nitrogen, trans to NS, parm99 values 
for N3 
      
BOND 
CB-NR  414.0    1.391              JCC,7,(1986),230; ADE,GUA, parm99 values for CB-NB 
CB-NS  414.0    1.391              JCC,7,(1986),230; ADE,GUA, parm99 values for CB-NB 
CK-NR  529.0    1.304              JCC,7,(1986),230; ADE,GUA, parm99 values for CK-NB 
CK-NS  529.0    1.304              JCC,7,(1986),230; ADE,GUA, parm99 values for CK-NB 
PT-NR  366.0    2.010              Marzilli InorgChem 33:6061-6067 (1994), Kr = 366 or 183 (183 
recommended for duplex DNA) 
PT-NS  366.0    2.010              Marzilli InorgChem 33:6061-6067 (1994), Kr = 366 or 183 (183 
recommended for duplex DNA) 
PT-N4  366.0    2.030              Marzilli InorgChem 33:6061-6067 (1994), Kr = 366 or 183 (183 
recommended for duplex DNA) 
PT-N5  366.0    2.030              Marzilli InorgChem 33:6061-6067 (1994), Kr = 366 or 183 (183 
recommended for duplex DNA) 
CT-N4  367.0    1.471              JCC,7,(1986),230; LYS, parm99 values for CT-N3 
CT-N5  367.0    1.471              JCC,7,(1986),230; LYS, parm99 values for CT-N3 
H -N4  434.0    1.010              JCC,7,(1986),230; LYS, parm99 values for H -N3 
H -N5  434.0    1.010              JCC,7,(1986),230; LYS, parm99 values for H -N3 
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ANGL 
C -CB-NR    70.0      130.00      parm99 values for C -CB-NB 
CB-CB-NR    70.0      110.40      parm99 values for CB-CB-NB 
H5-CK-NR    50.0      123.05      parm99 values for H5-CK-NB 
N*-CK-NR    70.0      113.90      parm99 values for N*-CK-NB 
CB-NR-CK    70.0      103.80      Scheef MolPharm 56:633-643 (1999), parm99 values for 
CB-NB-CK 
CB-NR-PT    20.0      127.95      Marzilli InorgChem 33:6061-6067 (1994) 
CK-NR-PT    20.0      127.95      Marzilli InorgChem 33:6061-6067 (1994) 
C -CB-NS    70.0      130.00      parm99 values for C -CB-NB 
CB-CB-NS    70.0      110.40      parm99 values for CB-CB-NB 
H5-CK-NS    50.0      123.05      parm99 values for H5-CK-NB 
N*-CK-NS    70.0      113.90      parm99 values for N*-CK-NB 
CB-NS-CK    70.0      103.80      Scheef MolPharm 56:633-643 (1999), parm99 values for 
CB-NB-CK 
CB-NS-PT    20.0      127.95      Marzilli InorgChem 33:6061-6067 (1994) 
CK-NS-PT    20.0      127.95      Marzilli InorgChem 33:6061-6067 (1994) 
NR-PT-NS    42.0       90.0       Marzilli InorgChem 33:6061-6067 (1994) 
N4-PT-N5    42.0       90.0       Marzilli InorgChem 33:6061-6067 (1994) 
N4-PT-NS    42.0       90.0       Marzilli InorgChem 33:6061-6067 (1994) 
N5-PT-NR    42.0       90.0       Marzilli InorgChem 33:6061-6067 (1994) 
N4-PT-NR    42.0      180.0       Marzilli InorgChem 33:6061-6067 (1994) 
N5-PT-NS    42.0      180.0       Marzilli InorgChem 33:6061-6067 (1994) 
PT-N4-H     50.0      109.5       MODFD Scheef MolPharm 56:633-643 (1999), parm99 values 
for CT-N3-H 
PT-N5-H     50.0      109.5       MODFD Scheef MolPharm 56:633-643 (1999), parm99 values 
for CT-N3-H 
H -N4-H     35.0      109.50      AA lys, AA(end), parm99 values for H -N3-H 
H -N5-H     35.0      109.50      AA lys, AA(end), parm99 values for H -N3-H 
PT-N4-CT    50.0      109.5       Scheef MolPharm 56:633-643 (1999), parm99 values for 
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CT-N3-H 
PT-N5-CT    50.0      109.5       Scheef MolPharm 56:633-643 (1999), parm99 values for 
CT-N3-H 
CT-N4-H     50.0      109.50      AA lys,     changed based on NMA nmodes, parm99 values for 
CT-N3-H 
CT-N5-H     50.0      109.50      AA lys,     changed based on NMA nmodes, parm99 values for 
CT-N3-H 
CT-CT-N4    80.0      111.20      AA lys             (JCP 76, 1439), parm99 values for 
CT-CT-N3 
CT-CT-N5    80.0      111.20      AA lys             (JCP 76, 1439), parm99 values for 
CT-CT-N3 
H1-CT-N4    50.0      109.50      changed based on NMA nmodes, parm99 values for H1-CT-N* 
H1-CT-N5    50.0      109.50      changed based on NMA nmodes, parm99 values for H1-CT-N* 
 
DIHE 
X -CB-NR-X    2    5.10        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
X -CB-NS-X    2    5.10        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
X -CK-NR-X    2   20.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
X -CK-NS-X    2   20.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
CB-CB-NR-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
C -CB-NR-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
N*-CK-NR-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
H5-CK-NR-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
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MolPharm 56 (1999) 
CB-CB-NS-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
C -CB-NS-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
N*-CK-NS-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
H5-CK-NS-PT   2    0.00        180.0             2.            parm99, MODFD Scheef 
MolPharm 56 (1999) 
CB-NR-PT-N5   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CK-NR-PT-N5   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CB-NR-PT-NS   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CK-NR-PT-NS   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CB-NR-PT-N4   1    0.00        0.00              2.            Scheef MolPharm 
56:633-643 (1999) 
CK-NR-PT-N4   1    0.00        0.00              2.            Scheef MolPharm 
56:633-643 (1999) 
CB-NS-PT-N4   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CK-NS-PT-N4   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CB-NS-PT-NR   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CK-NS-PT-NR   1    0.50        90.0              2.            Marzilli InorgChem 
33:6061-6067 (1994) 
CB-NS-PT-N5   1    0.00        0.00              2.            Scheef MolPharm 
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56:633-643 (1999) 
CK-NS-PT-N5   1    0.00        0.00              2.            Scheef MolPharm 
56:633-643 (1999) 
X -PT-N4-X    9    1.4         0.00              3.            Scheef MolPharm 56:633-643 
(1999) 
X -PT-N5-X    9    1.4         0.00              3.            Scheef MolPharm 56:633-643 
(1999) 
X -CT-N4-X    9    1.40        0.0               3.            JCC,7,(1986),230, parm99 
values for X -CT-N3-X 
X -CT-N5-X    9    1.40        0.0               3.            JCC,7,(1986),230, parm99 
values for X -CT-N3-X 
 
IMPR 
CK-CB-NR-PT         10.0         180.          2.              Marzilli InorgChem 
33:6061-6067 (1994) 
CK-CB-NS-PT         10.0         180.          2.              Marzilli InorgChem 
33:6061-6067 (1994) 
 
NONB 
  PT          2.44    0.400                                 Marzilli InorgChem 
33:6061-6067 (1994) diameter ==> radius 
  NR          1.8240  0.1700                                OPLS, parm99 
  NS          1.8240  0.1700                                OPLS, parm99 
  N4          1.8240  0.1700                                OPLS, parm99 
  N5          1.8240  0.1700                                OPLS, parm99 
 
 
New 
Atom Type 
Mass 
(1 AMU = 
1.66×10-27kg) 
Polarizability Reference   
PT 195.08         
NR 14.01 0.530  1     
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NS 14.01 0.530  1     
N4 14.01 0.530  1     
N5 14.01 0.530  1     
Bond pK (kcal/(mol·Å2)) 
Length 
(Å) Reference   
CB-NR 414.0 1.391  1     
CB-NS 414.0 1.391  1     
CK-NR 529.0 1.304  1     
CK-NS 529.0 1.304  1     
PT-NR 366.0 2.010  2     
PT-NS 366.0 2.010  2     
PT-N4 366.0 2.030  2     
PT-N5 366.0 2.030  2     
CT-N4 367.0 1.471  1     
CT-N5 367.0 1.471  1     
H-N4 434.0 1.010  1     
H-N5 434.0 1.010  1     
Angle pK (kcal/(mol·rad2)) 
Phase 
(º) Reference   
C-CB-NR 70.0 130.00  1     
CB-CB-NR 70.0 110.40  1     
H5-CK-NR 50.0 123.05  1     
N*-CK-NR 70.0 113.90  1     
CB-NR-CK 70.0 103.80  1, 3     
CB-NR-PT 20.0 127.95  2     
CK-NR-PT 20.0 127.95  2     
C-CB-NS 70.0 130.00  1     
CB-CB-NS 70.0 110.40  1     
H5-CK-NS 50.0 123.05  1     
N*-CK-NS 70.0 113.90  1     
CB-NS-CK 70.0 103.80  1, 3     
CB-NS-PT 20.0 127.95  2     
CK-NS-PT 20.0 127.95  2     
NR-PT-NS 42.0 90.00  2     
N4-PT-N5 42.0 90.00  2     
N4-PT-NS 42.0 90.00  2     
N5-PT-NR 42.0 90.00  2     
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N4-PT-NR 42.0 180.00  2     
N5-PT-NS 42.0 180.00  2     
PT-N4-H 50.0 109.50  1, 3*     
PT-N5-H 50.0 109.50  1, 3*     
H-N4-H 35.0 109.50  1     
H-N5-H 35.0 109.50  1     
PT-N4-CT 50.0 109.50  1, 3     
PT-N5-CT 50.0 109.50  1, 3     
CT-N4-H 50.0 109.50  1*     
CT-N5-H 50.0 109.50  1*     
CT-CT-N4 80.0 111.20  1     
CT-CT-N5 80.0 111.20  1     
H1-CT-N4 50.0 109.50  1*     
H1-CT-N5 50.0 109.50  1*     
Dihedral 
Angle Periodicity 
pK 
(kcal/mol) 
Phase 
(º) Periodicity Reference 
X-CB-NR-X 2 5.10 180.00 2  1, 3* 
X-CB-NS-X 2 5.10 180.00 2  1, 3* 
X-CK-NR-X 2 20.00 180.00 2  1, 3* 
X-CK-NS-X 2 20.00 180.00 2  1, 3* 
CB-CB-NR-PT 2 0.00 180.00 2  1, 3* 
C-CB-NR-PT 2 0.00 180.00 2  1, 3* 
N*-CK-NR-PT 2 0.00 180.00 2  1, 3* 
H5-CK-NR-PT 2 0.00 180.00 2  1, 3* 
CB-CB-NS-PT 2 0.00 180.00 2  1, 3* 
C-CB-NS-PT 2 0.00 180.00 2  1, 3* 
N*-CK-NS-PT 2 0.00 180.00 2  1, 3* 
H5-CK-NS-PT 2 0.00 180.00 2  1, 3* 
CB-NR-PT-N5 1 0.50 90.00 2  2 
CK-NR-PT-N5 1 0.50 90.00 2  2 
CB-NR-PT-NS 1 0.50 90.00 2  2 
CK-NR-PT-NS 1 0.50 90.00 2  2 
CB-NR-PT-N4 1 0.00 0.00 2  3 
CK-NR-PT-N4 1 0.00 0.00 2  3 
CB-NS-PT-N4 1 0.50 90.00 2  2 
CK-NS-PT-N4 1 0.50 90.00 2  2 
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CB-NS-PT-NR 1 0.50 90.00 2  2 
CK-NS-PT-NR 1 0.50 90.00 2  2 
CB-NS-PT-N5 1 0.00 0.00 2  3 
CK-NS-PT-N5 1 0.00 0.00 2  3 
X-PT-N4-X 9 1.40 0.00 3  3 
X-PT-N5-X 9 1.40 0.00 3  3 
X-CT-N4-X 9 1.40 0.00 3  1 
X-CT-N5-X 9 1.40 0.00 3  1 
Improper 
Torsion 
Angle 
pK 
(kcal/mol) 
Phase 
(º) Periodicity Reference  
CK-CB-NR-PT 10 180.00 2  2  
CK-CB-NS-PT 10 180.00 2  2  
Nonbond 
Interaction 
Van der Waals 
Radius 
pK 
(kcal/mol) Reference   
PT 2.440 0.40  2     
NR 1.824 0.17  1     
NS 1.824 0.17  1     
N4 1.824 0.17  1     
N5 1.824 0.17  1     
 
Table A.2 Force field parameters for Pt-GG adducts. AMU stands for atomic mass unit. pK is the 
penalty constant. The numbers in the reference columns stand for as follows: 1 for parameters from parm99 
force field of AMBER, 2 for parameters from work by Yao et al. and 3 for parameters from work by 
Scheeff et al. * indicates the parameter is modified based on the original one. The references for Yao et al. 
and Scheeff et al. are listed at the end of chapter 2. More detail is presented in the above script file. 
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APPENDIX B  MOLECULAR DYNAMICS SIMULATION PROTOCOL 
 
B.1 LEAP.scr 
 
# 
# Read in leaprc 
# 
source leaprc.ff99 
# 
# Set verbosity 
# 
verbosity 2 
# 
#       Load atom type hybridizations 
# 
addAtomTypes { 
        { "PT"  "Pt" "sp3" } 
        { "NR"  "N"  "sp2" } 
        { "NS"  "N"  "sp2" } 
        { "N4"  "N"  "sp3" } 
        { "N5"  "N"  "sp3" } 
} 
# 
#       Load platinum parameter set. 
# 
parmPT = loadAmberParams frcmod.PT 
# 
#       Load platinum libraries 
# 
loadOff PT.lib 
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# 
#       Load Generalized Born parameters 
# 
set default PBradii mbondi 
# 
#       Load pdb file 
# 
12mer_cp = loadPdb 12mer_cp.pdb 
# 
#       Generate new bonds 
# 
bond 12mer_cp.7.NB1 12mer_cp.25.PT 
bond 12mer_cp.6.NB2 12mer_cp.25.PT 
# 
#       Check unit and parmsets 
# 
check 12mer_cp parmPT 
edit 12mer_cp 
 
B.2 SANDER.scr 
 
#!/afs/isis/pkg/tcsh/bin/tcsh 
 
cat << eof1 > 12mer_cp_S.min1.in 
&cntrl 
 
   IMIN  =       1, 
   NTPR  =     100, 
 
   NTB   =       1, 
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   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   MAXCYC=    2000, 
   NCYC  =    5000, 
 
 &end 
 Restrain the DNA 
 500.0 
RES  1  28 
END 
END 
eof1 
 
cat << eof2 > 12mer_cp_S.md2.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       1, 
   IREST =       0, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       1, 
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   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   TEMPI =     0.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTC   =       2, 
 
 &end 
 Restrain the DNA 
 500.0 
RES  1  28 
END 
END 
eof2 
 
cat << eof3 > 12mer_cp_S.md3.in 
&cntrl 
 
   IMIN  =       0, 
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   NTX   =       5, 
   IREST =       1, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       2, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTP   =       1, 
   PRES0 =     1.0, 
   TAUP  =     0.2, 
   NTC   =       2, 
 
 &end 
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 Restrain the DNA 
 500.0 
RES  1  28 
END 
END 
eof3 
 
cat << eof4 > 12mer_cp_S.min4.in 
&cntrl 
 
   IMIN  =       1, 
   NTPR  =     100, 
 
   NTB   =       1, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   MAXCYC=    2000, 
   NCYC  =    5000, 
 
 &end 
 Weaken restraints on DNA 
 500.0 
RES  1  28 
END 
END 
eof4 
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cat << eof5 > 12mer_cp_S.min5.in 
&cntrl 
 
   IMIN  =       1, 
   NTPR  =     100, 
 
   NTB   =       1, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   MAXCYC=    2000, 
   NCYC  =    5000, 
 
 &end 
 Weaken restraints on DNA 
 50.0 
RES  1  28 
END 
END 
eof5 
 
cat << eof6 > 12mer_cp_S.min6.in 
&cntrl 
 
   IMIN  =       1, 
   NTPR  =     100, 
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   NTB   =       1, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   MAXCYC=    2000, 
   NCYC  =    5000, 
 
 &end 
 Weaken restraints on DNA 
 5.0 
RES  1  28 
END 
END 
eof6 
 
cat << eof7 > 12mer_cp_S.md7.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       1, 
   IREST =       0, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
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   NTF   =       2, 
   NTB   =       1, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   TEMPI =    10.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTP   =       0, 
   PRES0 =     1.0, 
   TAUP  =     0.2, 
   NTC   =       2, 
 
 &end 
 Weaken restraints on DNA 
 5.0 
RES  1  28 
END 
END 
eof7 
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cat << eof8 > 12mer_cp_S.md8.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       5, 
   IREST =       1, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       2, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTP   =       1, 
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   PRES0 =     1.0, 
   TAUP  =     0.2, 
   NTC   =       2, 
 
 &end 
 Weaken restraints on DNA 
 5.0 
RES  1  28 
END 
END 
eof8 
 
cat << eof9 > 12mer_cp_S.md9.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       5, 
   IREST =       1, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       2, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
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   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTP   =       1, 
   PRES0 =     1.0, 
   TAUP  =     0.2, 
   NTC   =       2, 
 
 &end 
 Weaken restraints on DNA 
 1.0 
RES  1  28 
END 
END 
eof9 
 
cat << eof10 > 12mer_cp_S.md10.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       5, 
   IREST =       1, 
   NTRX  =       1, 
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   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       2, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       1, 
 
   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTP   =       1, 
   PRES0 =     1.0, 
   TAUP  =     0.2, 
   NTC   =       2, 
 
 &end 
 Weaken restraints on DNA 
 0.1 
RES  1  28 
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END 
END 
eof10 
 
cat << eof11 > 12mer_cp_S.md11.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       5, 
   IREST =       1, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       2, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       0, 
 
   NSTLIM=   20000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   NTT   =       1, 
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   TAUTP =     0.2, 
 
   NTP   =       1, 
   PRES0 =     1.0, 
   TAUP  =     0.2, 
   NTC   =       2, 
 
 &end 
eof11 
 
cat << eof12 > 12mer_cp_S.md12.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       1, 
   IREST =       0, 
   NTRX  =       1, 
 
   NTPR  =     100, 
   NTWX  =       0, 
 
   NTF   =       2, 
   NTB   =       1, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       0, 
 
   NSTLIM=   20000, 
 74
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   TEMPI =    10.0, 
   NTT   =       1, 
   TAUTP =     0.2, 
 
   NTC   =       2, 
 
 &end 
eof12 
 
cat << eof13 > 12mer_cp_S.md0500.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       1, 
   IREST =       0, 
   NTRX  =       1, 
 
   NTPR  =     200, 
   NTWX  =     200, 
   NTWE  =     200, 
 
   NTF   =       2, 
   NTB   =       2, 
   NTC   =       2, 
   CUT   =     9.0, 
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   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       0, 
 
   NSTLIM=  500000, 
   NSCM  =    1000, 
   T     =     0.0, 
   DT    =   0.001, 
 
   TEMPI =   100.0, 
   TEMP0 =   300.0, 
   NTT   =       1, 
   TAUTP =     1.0, 
   IG    =   71277, 
 
   NTP   =       1, 
   PRES0 =     1.0, 
   TAUP  =     2.0, 
 
 &end 
eof13 
 
cat << eof14 > 12mer_cp_S.md1000.in 
&cntrl 
 
   IMIN  =       0, 
   NTX   =       5, 
   IREST =       1, 
   NTRX  =       1, 
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   NTPR  =     200, 
   NTWX  =     200, 
   NTWE  =     200, 
 
   NTF   =       2, 
   NTB   =       2, 
   NTC   =       2, 
   CUT   =     9.0, 
   NSNB  =      10, 
 
   IGB   =       0, 
   NTR   =       0, 
 
   NSTLIM=  500000, 
   NSCM  =    1000, 
   DT    =   0.001, 
 
   TEMP0 =   300.0, 
   NTT   =       1, 
   TAUTP =     1.0, 
 
   NTP   =       1, 
   PRES0 =     1.0, 
   TAUP  =     2.0, 
 
 &end 
eof14 
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mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.crd        \ 
                    -ref 12mer_cp_S.crd        \ 
                    -i   12mer_cp_S.min1.in    \ 
                    -inf 12mer_cp_S.min1.inf   \ 
                    -o   12mer_cp_S.min1.out   \ 
                    -r   12mer_cp_S.min1.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.min1.rstrt \ 
                    -ref 12mer_cp_S.min1.rstrt \ 
                    -i   12mer_cp_S.md2.in     \ 
                    -inf 12mer_cp_S.md2.inf    \ 
                    -o   12mer_cp_S.md2.out    \ 
                    -r   12mer_cp_S.md2.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md2.rstrt  \ 
                    -ref 12mer_cp_S.md2.rstrt  \ 
                    -i   12mer_cp_S.md3.in     \ 
                    -inf 12mer_cp_S.md3.inf    \ 
                    -o   12mer_cp_S.md3.out    \ 
                    -r   12mer_cp_S.md3.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md3.rstrt  \ 
                    -ref 12mer_cp_S.md3.rstrt  \ 
                    -i   12mer_cp_S.min4.in    \ 
                    -inf 12mer_cp_S.min4.inf   \ 
                    -o   12mer_cp_S.min4.out   \ 
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                    -r   12mer_cp_S.min4.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.min4.rstrt \ 
                    -ref 12mer_cp_S.min4.rstrt \ 
                    -i   12mer_cp_S.min5.in    \ 
                    -inf 12mer_cp_S.min5.inf   \ 
                    -o   12mer_cp_S.min5.out   \ 
                    -r   12mer_cp_S.min5.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.min5.rstrt \ 
                    -ref 12mer_cp_S.min5.rstrt \ 
                    -i   12mer_cp_S.min6.in    \ 
                    -inf 12mer_cp_S.min6.inf   \ 
                    -o   12mer_cp_S.min6.out   \ 
                    -r   12mer_cp_S.min6.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.min6.rstrt \ 
                    -ref 12mer_cp_S.min6.rstrt \ 
                    -i   12mer_cp_S.md7.in     \ 
                    -inf 12mer_cp_S.md7.inf    \ 
                    -o   12mer_cp_S.md7.out    \ 
                    -r   12mer_cp_S.md7.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md7.rstrt  \ 
                    -ref 12mer_cp_S.md7.rstrt  \ 
                    -i   12mer_cp_S.md8.in     \ 
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                    -inf 12mer_cp_S.md8.inf    \ 
                    -o   12mer_cp_S.md8.out    \ 
                    -r   12mer_cp_S.md8.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md8.rstrt  \ 
                    -ref 12mer_cp_S.md8.rstrt  \ 
                    -i   12mer_cp_S.md9.in     \ 
                    -inf 12mer_cp_S.md9.inf    \ 
                    -o   12mer_cp_S.md9.out    \ 
                    -r   12mer_cp_S.md9.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md9.rstrt  \ 
                    -ref 12mer_cp_S.md9.rstrt  \ 
                    -i   12mer_cp_S.md10.in    \ 
                    -inf 12mer_cp_S.md10.inf   \ 
                    -o   12mer_cp_S.md10.out   \ 
                    -r   12mer_cp_S.md10.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md10.rstrt \ 
                    -i   12mer_cp_S.md11.in    \ 
                    -inf 12mer_cp_S.md11.inf   \ 
                    -o   12mer_cp_S.md11.out   \ 
                    -r   12mer_cp_S.md11.rstrt 
 
mpirun -np 4 /afs/isis/pkg/amber-8/build/amber8/exe/sander -p   12mer_cp_S.top        \ 
                    -c   12mer_cp_S.md11.rstrt \ 
                    -i   12mer_cp_S.md12.in    \ 
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                    -inf 12mer_cp_S.md12.inf   \ 
                    -o   12mer_cp_S.md12.out   \ 
                    -r   12mer_cp_S.md12.rstrt 
 
mpirun -np 4 /opt/amber/exe/sander -p   12mer_cp_S.top          \ 
                    -c   12mer_cp_S.md12.rstrt   \ 
                    -i   12mer_cp_S.md0500.in    \ 
                    -inf 12mer_cp_S.md0500.inf   \ 
                    -o   12mer_cp_S.md0500.out   \ 
                    -x   12mer_cp_S.md0500.mdcrd \ 
                    -e   12mer_cp_S.md0500.mden  \ 
                    -r   12mer_cp_S.md0500.rstrt 
 
mpirun -np 4 /opt/amber/exe/sander -p   12mer_cp_S.top          \ 
                    -c   12mer_cp_S.md0500.rstrt \ 
                    -i   12mer_cp_S.md1000.in    \ 
                    -inf 12mer_cp_S.md1000.inf   \ 
                    -o   12mer_cp_S.md1000.out   \ 
                    -x   12mer_cp_S.md1000.mdcrd \ 
                    -e   12mer_cp_S.md1000.mden  \ 
                    -r   12mer_cp_S.md1000.rstrt 
 
